

1 **Microbial Energy Metabolism Fuels a CSF2-dependent Intestinal Macrophage**  
2 **Niche within Tertiary Lymphoid Organs**

3 Pailin Chiaranunt<sup>1</sup>, Kyle Burrows<sup>1</sup>, Louis Ngai<sup>1</sup>, Eric Y Cao<sup>1</sup>, Siu Ling Tai<sup>1</sup>, Helen Liang<sup>1</sup>,  
4 Homaira Hamidzada<sup>1,2</sup>, Anthony Wong<sup>1,2</sup>, Meggie Kuypers<sup>1</sup>, Tijana Despot<sup>1</sup>, Abdul  
5 Momen<sup>2</sup>, Sung Min Lim<sup>1</sup>, Thierry Malleavey<sup>1,3</sup>, Tyrrell Conway<sup>4</sup>, Hiromi Imamura<sup>5</sup>, Slava  
6 Epelman<sup>1,2</sup>, Arthur Mortha<sup>1\*</sup>

7 <sup>1</sup>Department of Immunology, University of Toronto, Toronto, ON, Canada

8 <sup>2</sup>Toronto General Hospital Research Institute, University Health Network, Toronto, ON,  
9 Canada. Peter Munk Cardiac Centre. Ted Rogers Centre for Heart Research.

10 <sup>3</sup>Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada

11 <sup>4</sup>Department of Microbiology and Molecular Genetics, Oklahoma State University,  
12 Stillwater, OK, USA

13 <sup>5</sup>Graduate School of Biostudies, Kyoto University, Kyoto, Japan

14 \*correspondence: [arthur.mortha@utoronto.ca](mailto:arthur.mortha@utoronto.ca)

15 **Summary**

16 Maintaining intestinal macrophage (MP) heterogeneity is critical to ensure tissue  
17 homeostasis and host defense. The gut microbiota and host factors are thought to  
18 synergistically shape colonic MP development, although there remains a fundamental  
19 gap in our understanding of the details of such collaboration. Here, we report tertiary  
20 lymphoid organs (TLOs), enriched in group 3 innate lymphoid cells (ILC3s), as a  
21 microbiota-operated intestinal niche for the development of monocyte-derived MPs. ILC3-

22 derived colony stimulating factor 2 (CSF2) serves as a developmental and functional  
23 determinant for MPs and required microbe-derived extracellular adenosine 5'-  
24 triphosphate (ATP) as a trigger. Microbial communities rich in extracellular ATP promoted  
25 MP turnover via ILC3 activity in an NLRP3-dependent fashion. Single cell RNA-  
26 sequencing of MPs revealed unique TLO-associated, CSF2-dependent MP populations  
27 critical for anti-microbial defense against enteric infection. Collectively, these findings  
28 describe a fundamental framework that constitutes an intestinal MP niche fueled by  
29 microbial energy metabolism.

### 30 **Introduction**

31 Intestinal macrophages (MPs) represent a large proportion of the innate immune system  
32 in the gut and are critical mediators of host defense and tissue homeostasis. Research in  
33 the past decade has revealed the extensive heterogeneity in these cells, from their  
34 differential ontogeny to their location-specific divisions of labor (Chiaranunt et al., 2021).  
35 However, mechanisms regulating MP heterogeneity in the intestinal lamina propria (LP)  
36 remain enigmatic, particularly regarding the involvement of microanatomic environments  
37 that balance the abundance of MPs involved in host defense and MPs regulating tissue  
38 homeostasis.

39 Further complicating this matter are the classification strategies for intestinal MPs. As in  
40 other organs, intestinal MP subpopulations can be distinguished based on their  
41 expression of the markers Tim-4 and CCR2 to denote fetal-derived long-lived, self-  
42 renewing, tissue resident cells and monocyte-derived ones, respectively (Dick et al.,  
43 2022; Kang et al., 2020). Others have demarcated gut MPs using Tim-4 and CD4 into 3  
44 subpopulations: long-lived Tim-4<sup>+</sup>CD4<sup>+</sup> MPs, Tim-4<sup>-</sup>CD4<sup>+</sup> MPs with slow monocytic

45 turnover, and Tim-4<sup>+</sup>CD4<sup>-</sup> MPs with rapid turnover (Liu et al., 2019; Shaw et al., 2018).  
46 Different populations of self-maintaining gut-resident MPs associate with neurons,  
47 vasculature, and other immune cells and reside in distinct regions of the gut, where they  
48 adopt transcriptional profiles and functions tailored to these microenvironments (De  
49 Schepper et al., 2018; Matheis et al., 2020; Muller et al., 2014). Unlike in most other  
50 organs, MPs within these intestinal microenvironments integrate signals derived from the  
51 commensal microflora into their homeostatic function (Mortha et al., 2014; Muller et al.,  
52 2014).

53 Several reports suggest that microbial metabolites affect intestinal MP function. For  
54 example, polysaccharides produced by *Helicobacter hepaticus* and commensal bacteria-  
55 derived short-chain fatty acids (SCFAs) were shown to promote tolerogenic MPs (Chang  
56 et al., 2014; Danne et al., 2017; Schulthess et al., 2019). Bacteria-metabolized dietary  
57 tryptophan controls monocyte differentiation in an aryl hydrocarbon receptor (AhR)-  
58 dependent manner (Goudot et al., 2017). Colonization with the protozoan commensal  
59 *Tritrichomonas musculus* (*T.mu*) was recently shown to induce monocyte infiltration in the  
60 gut by increasing luminal extracellular adenosine 5'-triphosphate (ATP) levels  
61 (Chiaranunt et al., 2022). This raises the question of whether a ubiquitously produced  
62 metabolite across microbial kingdoms may serve as a molecular motif to determine MP  
63 heterogeneity.

64 Microbiota and host-derived factors are proposed to collaborate in orchestrating gut MP  
65 composition and function. Deficiency in the host-derived myeloid growth factor colony  
66 stimulating factor 1 (CSF1) results in a systemic decrease in MPs, with a less pronounced  
67 effect on the intestinal tract, suggesting compensatory growth factors (Dai et al., 2002;

68 Sehgal *et al.*, 2018; Witmer-Pack *et al.*, 1993). Interleukin (IL)-34, transforming growth  
69 factor  $\beta$  (TGF $\beta$ ), or colony stimulating factor 2 (CSF2), have been reported to affect MP  
70 development in many organs, including the intestinal tract (Greter *et al.*, 2012; Guilliams  
71 *et al.*, 2013; Schridde *et al.*, 2017). In the gut, tissue-resident group 3 innate lymphoid  
72 cells (ILC3s) produce large quantities of CSF2 in a microbiota-dependent manner within  
73 intestinal tertiary lymphoid organs (TLOs), such as cryptopatches and isolated lymphoid  
74 follicles (Mortha *et al.*, 2014). *Csf2*<sup>-/-</sup> mice displayed a partial reduction in intestinal MPs,  
75 suggesting that MP development may in part depend on this growth factor (Mortha *et al.*,  
76 2014). CSF2 has recently been shown to license the effector profile of MPs in the inflamed  
77 brain, implicating an impact on MP function in addition to development (Amorim *et al.*,  
78 2022). Whether these observations on CSF2 extend to MP development and function in  
79 the intestine remain unknown.

80 Here, we report a molecular and spatial framework governing the collaboration between  
81 host and microbiota that regulates colonic MP heterogeneity. Combining fate-mapping  
82 models, immunofluorescence assays, microsurgical dissection, and single cell RNA-  
83 sequencing (scRNA-Seq) analysis, we identified TLOs as a supporting niche for the  
84 developmental and functional programming of monocyte-derived TLO-associated Tim-4<sup>+</sup>  
85 CD4<sup>+</sup> MPs. Using adoptive transfer experiments and mono-colonization of germ-free  
86 mice, we demonstrated that microbe-derived extracellular ATP serves as a driver of CSF2  
87 production by ILC3s in an NLRP3-dependent fashion to induce the monocyte to MP  
88 transition. TLO-associated MPs expressed distinct genes, displayed high metabolic  
89 demand, and followed an alternative differentiation pathway compared to LP-resident  
90 MPs. Development of TLO-associated MPs was dependent on CSF2 and protected the

91 host against enteric bacterial infections. Collectively, our findings identify a molecular and  
92 spatial framework for the location-specific differentiation of colonic MPs, centered around  
93 a microbiota-fueled, ILC3-driven and CSF2-dependent axis that integrates signals  
94 indicative of microbial energy into the heterogeneity of colonic MPs.

## 95 **Results**

### 96 **Colonic monocyte-derived MPs require CSF2**

97 Tissue-resident MPs in extra-intestinal organs group into monocyte- or fetal-derived  
98 subpopulations based on cross-organ conserved expression of the markers CCR2, Tim-  
99 4, LYVE1, and MHCII (Dick *et al.*, 2022). In the gut, MPs have been classified by Tim-4  
100 and CD4 expression and the ‘monocyte waterfall’ gating strategy (Bain *et al.*, 2014; Shaw  
101 *et al.*, 2018). To consolidate these various gating strategies, we performed an unbiased  
102 t-distributed stochastic neighbor embedding (t-SNE) dimensionality reduction on colonic  
103 lamina propria (LP) CD64<sup>+</sup> CD11b<sup>+</sup> cells. Distinct and partial overlap in the expression of  
104 Tim-4, CD4, CCR2, MHCII, and Ly6C aligned with the previous classification into Tim-  
105 4<sup>+</sup>CD4<sup>+</sup>, Tim-4<sup>-</sup>CD4<sup>+</sup>, and Tim-4<sup>-</sup>CD4<sup>-</sup> MPs. Tim-4<sup>-</sup>CD4<sup>-</sup> MPs were further delineated into  
106 Ly6C<sup>+</sup>, CCR2<sup>+</sup>, and CCR2<sup>-</sup> MPs, suggesting a developmental relationship to monocytes  
107 (**Fig 1A, Fig S1A,B**)(Dick *et al.*, 2022; Shaw *et al.*, 2018). Accordingly, Tim-4<sup>-</sup>CD4<sup>-</sup> MPs  
108 were significantly depleted in *Ccr2*<sup>-/-</sup> mice, leaving Tim-4<sup>+</sup> MPs as the majority of colonic  
109 MPs in these mice (**Fig 1B**). Previous investigations into *Csf2*<sup>-/-</sup> mice did not use this  
110 detailed classification of MPs, prompting us to revisit the requirements for CSF2 on gut  
111 MP heterogeneity (Mortha *et al.*, 2014). Analysis of MPs in the colonic LP of *Csf2*<sup>-/-</sup> mice  
112 revealed an elevated abundance of Ly6C<sup>hi</sup> monocytes compared to WT or *Ccr2*<sup>-/-</sup> mice,  
113 implicating a developmental blockade on the transition from monocytes to MPs (**Fig S1C**).  
114 CCR2<sup>+</sup> and CCR2<sup>-</sup> Tim-4<sup>-</sup>CD4<sup>-</sup> MPs and Tim-4<sup>-</sup>CD4<sup>+</sup> MPs were reduced in *Csf2*<sup>-/-</sup> mice,

115 further implicating their developmental relation to monocytes (**Fig 1B, Fig S1C**). Tim-4<sup>+</sup>  
116 MPs were partially affected in *Csf2*<sup>-/-</sup> mice, suggesting that all MP subpopulations variably  
117 depend on this growth factor (**Fig 1B, Fig S1C**).

118 Tim-4<sup>+</sup> MPs are a long-lived, fetal-derived population with minimal replacement by  
119 monocytes. It has further been proposed that the expression of Tim-4 may reflect long-  
120 term residency within a tissue following differentiation (Bleriot et al., 2020; De Schepper  
121 et al., 2018; Scott et al., 2016; Shaw et al., 2018; Theurl et al., 2016). To determine the  
122 long-term MP turnover by infiltrating monocytes, we performed parabiosis of CD45.1  
123 C57BL/6 and CD45.2 *Ccr2*<sup>-/-</sup> mice to assess the chimerism of each MP subpopulation  
124 after 6 or 12 months. As expected, *Ccr2*<sup>-/-</sup> parabionts showed CD45.1 frequencies  
125 comparable to blood monocytes in both the colonic Tim-4<sup>-</sup>CD4<sup>-</sup> MP s and Tim-4<sup>-</sup>CD4<sup>+</sup> MP  
126 compartments (**Fig 1C**). Surprisingly, Tim-4<sup>+</sup> MPs were also replaced by donor CD45.1  
127 monocytes, albeit at a slower rate, suggesting a homeostatic contribution of monocytes  
128 to the maintenance of Tim-4<sup>+</sup> MPs (**Fig 1C**). To confirm our results, we employed a  
129 tamoxifen-inducible fate-mapping model. Tamoxifen-containing chow was provided to  
130 *Ccr2*<sup>CreERT2</sup> x *Rosa26*-LSL-tdTomato (*Rosa26*<sup>td</sup>) mice during a 1-week pulse phase,  
131 followed by a chase period with normal chow for either 1 or 52 week(s). Loss of Tomato  
132 labeling was measured in each MP subpopulation to assess the replacement of MPs by  
133 newly infiltrated monocytes. Tamoxifen administration labelled ~94% of all blood Ly6C<sup>hi</sup>  
134 monocytes within the 1-week pulse phase. The induced Tomato label was absent in  
135 monocytes after 52 weeks (**Fig 1D**). Colonic Ly6C<sup>+</sup> monocytes and Tim-4<sup>-</sup>CD4<sup>-</sup> MPs  
136 showed labeling efficiency similar to blood monocytes, while Tim-4<sup>-</sup>CD4<sup>+</sup> MPs displayed  
137 partial Tomato labeling (64%). Surprisingly, ~17% of all Tim-4<sup>+</sup> MPs were labeled after

138 the 1-week pulse phase, suggesting a possible contribution of monocytes to this  
139 population during tamoxifen administration (**Fig 1D**). After the first 7 days of the chase  
140 period, Tim-4<sup>-</sup>CD4<sup>-</sup> MPs (containing Ly6C<sup>+</sup> and CCR2<sup>+</sup> cells) displayed replacement by  
141 bone marrow-derived (BM) monocytes, as indicated by the loss of Tomato labelling (**Fig**  
142 **1D**). Tim-4<sup>-</sup>CD4<sup>+</sup> MPs and Tim-4<sup>+</sup> MPs did not show signs of replacement, suggesting a  
143 slower replacement rate in line with our parabiosis experiments (**Fig 1C, 1D**). After the  
144 52-week chase period, all MP subpopulations lost the Tomato label (**Fig 1D**). These  
145 results indicate that all colonic MPs share a monocytic origin, with Tim-4<sup>-</sup>CD4<sup>-</sup> MPs  
146 showing the fastest replacement and strongest reliance on CSF2.

#### 147 **Diversified microbiotas promote the accumulation of Tim-4<sup>-</sup>CD4<sup>-</sup> MPs**

148 Tissue-resident Tim-4<sup>+</sup> MPs dominate the MP pool during embryogenesis and are found  
149 in all tissues at early time points of fetal development, while Tim-4<sup>-</sup> MPs postnatally arise  
150 from BM monocytes (Dick *et al.*, 2022). In the gut, this development requires the  
151 microbiota (Bain *et al.*, 2014; Shaw *et al.*, 2018). Our fate-mapping and parabiosis data  
152 show that colonic MP subpopulations display different rates of monocyte replacement,  
153 suggesting distinct appearances of the MP subpopulations in the neonatal and adult  
154 intestine. To delineate the developmental kinetics of colonic MPs, we assessed the  
155 composition of MPs starting in the neonatal colon, tracking along the first weeks of life  
156 until adulthood. In line with previous reports, embryonically-derived Tim-4<sup>+</sup>CD4<sup>+</sup> MPs  
157 primarily comprise the colons of newborn mice, followed by a significantly increased  
158 abundance of Tim-4<sup>-</sup>CD4<sup>-</sup> MPs at 3-4 weeks of age. This time corresponds to weaning  
159 and the establishment of a diversified microbiota (**Fig 2A**)(Knoop *et al.*, 2017). By 8-12  
160 weeks after birth, Tim-4<sup>-</sup>CD4<sup>-</sup> MPs comprise the majority of colonic MPs, implicating a

161 microbiota-driven adaptation of the MP pool. These adaptations in gut MPs mirror  
162 previously reported observations of intestinal CSF2 production, which similarly increased  
163 until week 8 in a microbiota-dependent fashion (Mortha *et al.*, 2014). Depletion of the  
164 microbiota using broad-spectrum antibiotics in adult mice shifted the MP pool in favor of  
165 Tim-4<sup>+</sup>CD4<sup>+</sup> MPs, confirming a requirement of the microbiota in regulating MP  
166 composition (**Fig 2B**). In contrast, reconstituting germ-free mice with an adult SPF  
167 microbiota increased Tim-4<sup>-</sup>CD4<sup>-</sup> MPs at the expense of Tim-4<sup>+</sup>CD4<sup>+</sup> MPs (**Fig 2C**).  
168 Colonization of adult SPF mice with the protozoan commensal *T. mu* further increased  
169 the abundance of Tim-4<sup>-</sup>CD4<sup>-</sup> MPs (**Fig 2D**). A comparable shift towards Tim-4<sup>-</sup>CD4<sup>-</sup> MPs  
170 was also observed when analyzing “re-wilded” mice, i.e. ex-SPF mice that were colonized  
171 with the microbiota found in pet-store mice (**Fig 2E**). These findings suggest that the  
172 increase in Tim-4<sup>-</sup>CD4<sup>-</sup> MPs in the colon may be due to an increase in microbiota-driven  
173 monocyte replacement. To track the rate of monocyte replacement in the colon, we  
174 labeled all *Cx3cr1*-expressing cells in tamoxifen-inducible *Cx3cr1*<sup>CreERT2</sup> x *Rosa26*<sup>td</sup> mice  
175 and followed the loss of Tomato labeling in each MP population after colonization with *T.*  
176 *mu* (**Fig 2F**). Compared to uncolonized littermate controls, *T. mu*-colonized mice showed  
177 significantly reduced percentages of Tomato<sup>+</sup> cells particularly in Tim-4<sup>-</sup>CD4<sup>-</sup> MPs,  
178 suggesting an increased replacement of these cells by Tomato<sup>-</sup> monocytes (**Fig 2G**). In  
179 support of our fate mapping and parabiosis data, monocyte replacement was also  
180 elevated in Tim-4<sup>-</sup>CD4<sup>+</sup> MPs and Tim-4<sup>+</sup>CD4<sup>+</sup> MPs. Collectively, our data demonstrate  
181 that diversifying the gut microbiota promotes MP replacement by monocytes and the  
182 accumulation of Tim-4<sup>-</sup>CD4<sup>-</sup> MPs. Notably, colonization with *T. mu* has previously been



183 found to increase the production of CSF2 by ILC3s in the intestinal tract, implicating a  
184 role for ILC3s in the elevated MP replacement rates (Chudnovskiy *et al.*, 2016).

### 185 **Microbial extracellular ATP regulates MP composition and CSF2 production**

186 Diversification of the microbiota manifests multiple new features within the microbial  
187 community, including adaptations to nutrients and synthesis of different metabolites (Blaut  
188 and Clavel, 2007). Such changes may not apply to individual microbial species but rather  
189 reflect a feature of complex community interactions (Patnode *et al.*, 2021). This raises  
190 the possibility for a conserved ubiquitously produced metabolite across all living microbes  
191 that indicates microbial vitality, but at the same time, serves as a molecular motif for  
192 immune recognition and activation that can indirectly impact MP homeostasis. ATP is one  
193 such metabolite capable of promoting intestinal immunity (Atarashi *et al.*, 2008). We  
194 recently demonstrated that colonization with the protozoan commensal *T. mu* induces  
195 immune activation in the colon, including increased monocyte infiltration, regulated by  
196 elevated intestinal extracellular ATP (ATP<sup>ex</sup>) levels and inflammasome activation  
197 (Chiaranunt *et al.*, 2022). ATP<sup>ex</sup> is a common danger associated molecular pattern  
198 (DAMP) that correlates with the presence of the microbiota and subsequently regulates  
199 local adaptive immune cells through P2X7R-dependent recognition by CD11c<sup>+</sup> myeloid  
200 cells (Atarashi *et al.*, 2008; Perruzza *et al.*, 2017). Thus, we asked whether ATP<sup>ex</sup> might  
201 serve as a rheostatic indicator of the microbiota, capable of regulating colonic MP  
202 composition. In line with previous studies, we first confirmed that levels of ATP<sup>ex</sup> in the  
203 gut lumen corresponded to abundance of the microbiota by comparing fecal ATP<sup>ex</sup> in  
204 SPF, antibiotics-treated, and germ-free mice (**Fig 3A**). ATP was shown to be released by  
205 multiple bacterial species through an unknown mechanism while undergoing cellular

206 respiration during the growth phase *in vitro* to prolong their stationary survival (Mempin  
207 et al., 2013). To specifically investigate whether bacteria-derived ATP could regulate MPs  
208 in the gut, we utilized a mutant strain of commensal *E. coli* MG1655 that lacks the operons  
209 encoding the ATP synthase subunits A-G ( $\Delta(atpA-atpG)$ ) (Jones et al., 2007). In contrast  
210 to wild-type *E. coli* or a mutant lacking nitrate reductase genes ( $\Delta narG \Delta narZ \Delta(napD-$   
211  $napA)$ ), the ATPase-deficient mutant was unable to secrete ATP during growth *in vitro*,  
212 confirming an ATPase-dependent increase in ATP<sup>ex</sup> (**Fig S2A,B**). Transformation of the  
213 Förster resonance energy transfer (FRET)-type ATP biosensor ATeam 3.10 into these *E.*  
214 *coli* strains enabled the quantification of intracellular ATP (ATP<sup>int</sup>) levels (**Fig S2C**)  
215 (Imamura et al., 2009). Accordingly, less pronounced ATP<sup>int</sup> levels were observed in the  
216 ATPase-deficient *E. coli in vitro*, confirming its metabolic impairment and release of ATP  
217 (**Fig S2D,E**).

218 To determine whether an impaired ATP metabolism in commensals impacts MP  
219 heterogeneity in the gut, GF mice were mono-colonized with either control or  $\Delta(atpA-$   
220  $atpG)$  *E. coli*. The colonic MP composition was assessed 7 days after engraftment to  
221 avoid confounding effects of adaptive immune cells on the colonizing microbes  
222 (Hapfelmeier et al., 2010; Macpherson and Uhr, 2004). Despite equal colonization,  
223  $\Delta(atpA-atpG)$  *E. coli* produced less ATP<sup>int</sup> at the time of analysis compared to the wild-  
224 type control strain (**Fig S2F,G**). Accordingly, mice colonized with control *E. coli* showed  
225 higher infiltration of Ly6C<sup>+</sup> and CCR2<sup>+</sup> MPs in comparison to  $\Delta(atpA-atpG)$  *E. coli-*  
226 colonized mice (**Fig 3B,C**). CSF2 governed the abundance of CCR2<sup>+</sup> MPs and has  
227 previously been reported to be produced by ILC3s in a microbiota-dependent manner  
228 (Mortha et al., 2014; Satoh-Takayama et al., 2008). To determine the impact of ATP<sup>ex</sup> on

229 ILC3s, we analyzed CSF2 release and ILC3 counts in the colonic LP of untreated GF  
230 mice versus mice mono-colonized with  $\Delta(atpA-atpG)$  or control *E. coli*. Notably, only mice  
231 gavaged with wild-type *E. coli* but not  $\Delta(atpA-atpG)$  showed an increase in ILC3 numbers  
232 and CSF2 release, implicating the regulation of CSF2-producing ILC3s by microbe-  
233 derived ATP<sup>ex</sup> (**Fig 3D**). In support of these data, decreased CSF2 production by ILC3s  
234 was observed in *Nlrp3<sup>-/-</sup>* and *P2rx7<sup>-/-</sup>* mice, deficient in initiating ATP<sup>ex</sup>-dependent  
235 inflammasome activation (**Fig 3E**). Altogether, these data indicate that microbe-derived  
236 ATP<sup>ex</sup> regulates colonic monocyte-derived MPs and the production of CSF2 by ILC3s via  
237 the inflammasome.

### 238 **CSF2-producing ILC3s support intestinal CCR2<sup>+</sup> Tim-4<sup>-</sup>CD4<sup>-</sup> MPs**

239 Microenvironmental cues within anatomical niches are critical for imprinting tissue-  
240 resident MP identity in various organs (Guilliams *et al.*, 2020). However, less focus has  
241 been placed on niches for monocyte-derived MPs. In the gut, CSF2-producing ILC3s are  
242 abundantly found within postnatally formed tertiary lymphoid organs (TLOs), such as  
243 cryptopatches and isolated lymphoid follicles (Mortha *et al.*, 2014). These data prompted  
244 us to determine whether CSF2-producing ILC3s constitute supporting cells for monocyte-  
245 derived MPs in the colon. In support of our hypothesis, live imaging of *Rorc<sup>+/-</sup>EGFP Ccr2<sup>+/-</sup>RFP*  
246 colons revealed an accumulation of CCR2<sup>+</sup> cells along the edges of TLOs, surrounding  
247 ROR $\gamma$ <sup>t</sup> ILC3s within the structures (**Fig 4A**). To confirm that these CCR2<sup>+</sup> cells  
248 surrounding TLOs are MPs, we quantified CX3CR1<sup>+</sup>CCR2<sup>+</sup> MPs in the LP or TLOs of the  
249 colon in immunofluorescence images from *Cx3cr1<sup>+/-</sup>EGFP Ccr2<sup>+/-</sup>RFP* mice. CCR2<sup>+</sup> MPs  
250 displayed an elevated accumulation within TLOs compared to the surrounding LP (**Fig**  
251 **4B,C**). TLOs have been reported to contain B cells and T cells (Hamada *et al.*, 2002). To

252 determine whether B and T cells were involved in shaping intestinal MP heterogeneity,  
253 MP composition was analyzed in WT, *Rag2*<sup>-/-</sup> and *Rag2*<sup>-/-</sup>*Il2rg*<sup>-/-</sup> mice. Interestingly, only  
254 *Rag2*<sup>-/-</sup>*Il2rg*<sup>-/-</sup> mice (lacking all lymphocytes), but not *Rag2*<sup>-/-</sup> mice (sufficient in ILCs),  
255 displayed a significant reduction in colonic Tim-4<sup>-</sup>CD4<sup>-</sup> MPs that was comparable to the  
256 decrease observed in *Csf2*<sup>-/-</sup> mice. These findings indicate that ILCs but not T and B cells  
257 regulate the homeostatic CSF2-dependent MP composition in the colon (**Fig 4D**). In line  
258 with this, adoptive transfer of 10<sup>4</sup> FACS-purified *Rorc*<sup>+EGFP</sup> ILC3s from WT (ILC3<sup>CSF2</sup>) or  
259 *Csf2*<sup>-/-</sup> (ILC3<sup>ΔCSF2</sup>) mice into *Rag2*<sup>-/-</sup>*Il2rg*<sup>-/-</sup> recipients revealed a significant accumulation  
260 of Tim-4<sup>-</sup>CD4<sup>-</sup> MPs in the colonic LP after 6 weeks (**Fig 4E, S4A**). The accumulation of  
261 Tim-4<sup>-</sup>CD4<sup>-</sup> MPs was critically dependent on ILC3-derived CSF2 (**Fig 4E, S4B**). Notably,  
262 numbers of Tim-4<sup>-</sup>CD4<sup>+</sup> and Tim-4<sup>+</sup>CD4<sup>+</sup> MPs were also slightly increased in *Rag2*<sup>-/-</sup>*Il2rg*<sup>-/-</sup>  
263 <sup>-/-</sup> mice after transfer of ILC3<sup>CSF2</sup>, suggesting a partial dependency of this subpopulation  
264 on CSF2-producing ILC3s (**Fig 4F**). In summary, these findings demonstrate that CCR2<sup>+</sup>  
265 MPs accumulate around colonic TLOs and that colocalization with CSF2-producing ILC3s  
266 supports Tim-4<sup>-</sup>CD4<sup>-</sup> MPs in the colon.

### 267 **scRNA-Seq reveals unique TLO-associated MP populations**

268 To incorporate spatial information into the actions of CSF2 on colonic MPs at higher  
269 granularity, we performed scRNA-Seq analysis of MPs isolated from either the TLOs or  
270 LP of WT or *Csf2*<sup>-/-</sup> mice. Live *Cx3cr1*<sup>+EGFP</sup>*Ccr2*<sup>+RFP</sup> colonic tissues revealed TLOs and  
271 LP using a fluorescence stereomicroscope (**Fig 5A**). Biopsy punches containing colonic  
272 TLOs or LP, free of TLOs, were isolated and digested prior to enrichment for CD11b<sup>+</sup>  
273 cells by magnetic beads (>90% purity) and subsequent scRNA-Seq analysis (**Fig 5B**).  
274 UMAP dimensionality reduction and combined analysis of all 4 groups (LP<sup>WT</sup>, TLO<sup>WT</sup>,

275 LP<sup>Csf2<sup>-/-</sup></sup>, TLO<sup>Csf2<sup>-/-</sup></sup>) yielded 18 clusters from a total of 15,369 cells (**Fig S4A**). Based on  
276 their top 30 cluster-defining genes, we identified clusters corresponding to B cells  
277 (clusters 7, 10), T/NK cells (cluster 14), and epithelial and stromal cells (clusters 0, 5, 6,  
278 9, 11, 15-17), which were excluded from subsequent analysis (**Fig S4B**). DC clusters (3,  
279 12, 13) were identified based on *Flt3*, *Dpp4*, *Zbtb46*, and *Itgax* expression. The remaining  
280 clusters (1, 2, 4, 8) were identified as MPs and monocytes based on their expression of  
281 *Csf1r*, *Cx3cr1*, and *C1qa* and absence of DC markers (**Fig S4C, D**).

282 Subsetting and re-analysis of the MP/monocyte clusters resulted in 9 distinct clusters,  
283 revealing substantial heterogeneity within the colonic MP pool (**Fig 5C**). Cells within  
284 clusters 0, 1, and 7 were enriched in the LP, while TLOs primarily comprised clusters 2,  
285 3, 5, and 6, indicating preferential localization of some MP subpopulations within these  
286 structures (**Fig 5D**). Each MP cluster was then identified based on their top 30 cluster-  
287 defining genes (**Fig 5E**). MPs in clusters 0 and 5 highly expressed *Lyve1*, *Mrc1*, *Maf*, and  
288 *Timd4*, thus corresponding to tissue-resident Tim-4<sup>+</sup> MPs (De Schepper *et al.*, 2018; Dick  
289 *et al.*, 2022; Moura Silva *et al.*, 2021). MPs in clusters 0 and 5 co-expressed *Cd4* but not  
290 *Ccr2*, consistent with our flow cytometric classification (**Fig 5F**). Interestingly, MPs in  
291 cluster 5, enriched in the TLO, expressed higher levels of *Folr2*, which was shown to be  
292 expressed in gut and brain c-MAF-dependent perivascular MPs involved in metabolic  
293 regulation (Moura Silva *et al.*, 2021). Consistent with previous reports, pathway analysis  
294 demonstrated that MPs in clusters 0 and 5 were enriched in endocytosis and vesicle-  
295 mediated transport pathways and mediated tissue homeostatic functions, including  
296 synapse pruning (**Fig 5G, Fig S4E**). These observations prompted us to label MP clusters  
297 0 and 5 as Tim-4<sup>+</sup> LP MPs and Tim-4<sup>+</sup> TLO MPs, respectively. We also identified clusters

298 corresponding to CCR2<sup>+</sup> MPs (cluster 1), monocytes (cluster 4), Tim-4<sup>-</sup>CD4<sup>+</sup> MPs (cluster  
299 6), RELM $\alpha$ <sup>+</sup> MPs (cluster 7), and epithelium/endothelium-associated *Pecam1*<sup>+</sup> MPs  
300 (cluster 8) (**Fig 5E,F**). Although previous reports identified Tim-4<sup>-</sup>CD4<sup>+</sup> MPs and  
301 investigated their developmental kinetics, the functions of this subpopulation remain  
302 unclear (Shaw *et al.*, 2018). Interestingly, cluster 6 MPs, corresponding to Tim-4<sup>-</sup>CD4<sup>+</sup>  
303 MPs, displayed a gene expression pattern similar to that reported in inflammatory  
304 microglia and border-associated MPs, including expression of *Apoe*, *Ms4a7*, and  
305 *Tmem119* (Amorim *et al.*, 2022; De Schepper *et al.*, 2018; Sankowski *et al.*, 2019; Satoh  
306 *et al.*, 2016). Pathway analysis on MP cluster 6 indicated that Tim-4<sup>-</sup>CD4<sup>+</sup> MPs are  
307 involved in leukocyte activation, antigen presentation, T cell activation, and NF- $\kappa$ B  
308 signaling, suggesting a pro-inflammatory role for this subpopulation (**Fig 5G, S4E**).

309 Interestingly, cluster 2 and 3 MPs were found almost exclusively in TLOs and expressed  
310 high levels of *Il22ra2* and *Lyz1*, markers reported for TLO-residing CD11c<sup>+</sup>MHCII<sup>+</sup>CD11b<sup>-</sup>  
311 CD103<sup>-</sup> DCs in the small intestine (Guendel *et al.*, 2020). However, we confirmed the MP  
312 identity for cluster 2 and 3 cells based on their expression of MP markers (*Csf1r*, *Cx3cr1*,  
313 *C1qa*, *Adgre1*, and *Fcgr1*) and the absence of DC markers (*Flt3*, *Dpp4*, and *Zbtb46*) (**Fig**  
314 **S4B,C**). The absence of *Timd4* and *Cd4* expression and low level of *Ccr2* expression in  
315 cluster 2 and 3 MPs suggest that these cells correspond to a subset of the Tim-4<sup>-</sup>CD4<sup>-</sup>  
316 MPs (**Fig 5F**). These MPs were enriched in ATP metabolism, oxidative phosphorylation,  
317 and phagocytic pathways, indicative of a population high in energy demand (**Fig 5G,**  
318 **S4E**). To determine the developmental relationship between TLO-enriched and LP-  
319 enriched MP clusters, we performed trajectory analysis using Monocle 3 with Seurat-  
320 generated clusters overlaid, which revealed a common origin for all MPs within the

321 monocyte cluster 4, confirming our fate-mapping and parabiosis studies (**Fig 5H**).  
322 Pseudotime analysis revealed a gradual loss of *Ly6c2* and *Ccr2* expression and gain of  
323 *Cd4* and *Timd4* expression as cells transition from monocytes towards differentiated MPs  
324 (**Fig 5H**). Importantly, Tim-4<sup>+</sup>CD4<sup>+</sup> MPs represent a differentiation branching point, at  
325 which cells either transition into Tim-4<sup>+</sup> MPs (clusters 0 and 4) or into TLO-associated  
326 MPs (first to cluster 3, then cluster 2) (**Fig 5H**). Given that Tim-4<sup>+</sup>CD4<sup>+</sup> MPs were least  
327 affected by perturbations in the microbiota (**Fig 2**), their status as a defining branchpoint  
328 for tissue-resident MPs may be worth additional investigation in the future. In summary,  
329 our scRNA-Seq analyses reveal a novel TLO-associated Tim-4<sup>+</sup>CD4<sup>-</sup> MP population, high  
330 in energy metabolism and possibly originating from Tim-4<sup>+</sup>CD4<sup>+</sup> MPs along a distinct  
331 differentiation pathway.

### 332 **CSF2 is a spatial determinant of MP development and function in the colon**

333 To determine whether TLO MPs may be regulated by CSF2, we first identified CSF2-  
334 responsive MP clusters based on their *Csf2ra* and *Csf2rb* expression. All MP clusters with  
335 the exception of *Timd4<sup>+</sup>Lyve1<sup>+</sup>* MPs (clusters 0, 5, and 8) expressed detectable levels of  
336 *Csf2ra* and *Csf2rb* (**Fig 6A**). Comparison of MP cluster composition in WT and *Csf2<sup>-/-</sup>*  
337 TLOs revealed a loss in the relative abundance of cluster 2 and 3 MPs in TLO<sup>*Csf2<sup>-/-</sup>*</sup> (**Fig**  
338 **6B**). Surprisingly, Tim-4<sup>+</sup> LP MPs (cluster 0) were reduced in the LP<sup>*Csf2<sup>-/-</sup>*</sup>, even in the  
339 absence of *Csf2ra* and *Csf2rb* mRNAs (**Fig 6B**). We hypothesized that CSF2 deficiency  
340 renders colonic monocytes and CCR2<sup>+</sup> MPs unable to differentiate and undergo  
341 apoptosis, based on CSF2's role as a pro-survival factor for myeloid cells (Wan *et al.*,  
342 2013). An assessment of apoptosis in colonic MPs revealed an increase in apoptotic

343 Ly6C<sup>+</sup> and Tim-4<sup>-</sup>CD4<sup>-</sup> MPs in *Csf2*<sup>-/-</sup> mice, the latter corresponding to the loss of TLO  
344 MPs in TLO<sup>*Csf2*<sup>-/-</sup></sup> (**Fig S5**).

345 CSF2 promotes the transition of monocyte to MPs in the inflamed brain, specifically by  
346 supporting disease-promoting functions in MPs (Amorim *et al.*, 2022). These new findings  
347 are in contrast to our data showing CSF2-driven pathways in steady state colonic MPs.  
348 Pathway analysis based on differential gene expression of each cluster in each region of  
349 WT versus *Csf2*<sup>-/-</sup> mice revealed significant differences in multiple MP clusters, even  
350 those devoid of *Csf2ra* or *Csf2rb* mRNAs (**Fig 6C**). Within the LP<sup>*Csf2*<sup>-/-</sup></sup>, Tim-4<sup>+</sup> (red) and  
351 CCR2<sup>+</sup> (orange) MPs were impaired in cytoskeleton organization, migration, and  
352 endocytosis, but enriched in pro-inflammatory processes like T cell activation, antigen  
353 activation, leukocyte-mediated cytotoxicity, and the response to biotic stimuli (**Fig 6C**).  
354 However, an even larger number of MP clusters were affected in TLO<sup>*Csf2*<sup>-/-</sup></sup>. Similar to  
355 LP<sup>*Csf2*<sup>-/-</sup></sup> Tim-4<sup>+</sup> MP, homeostasis of TLO<sup>*Csf2*<sup>-/-</sup></sup> Tim-4<sup>+</sup> (aqua) MPs was impaired as shown  
356 by altered synapse pruning and wound healing functions, and upregulated pro-  
357 inflammatory pathways (**Fig 6C**). Tim-4<sup>-</sup>CD4<sup>+</sup> (dark blue) MPs followed these trends  
358 towards altered homeostasis and increased inflammation. Conversely, clusters  
359 corresponding to monocytes (green) and CCR2<sup>+</sup> MPs downregulated pathways involved  
360 in response to stimuli and were enriched in pathways related to cell survival, glycolipid  
361 catabolism and protein stabilization in TLO<sup>*Csf2*<sup>-/-</sup></sup>, confirming the increased apoptosis in  
362 *Csf2*<sup>-/-</sup> mice (**Fig S5A and 6C**). These data show that CSF2 deficiency induces the  
363 functional dysregulation of multiple colonic MP populations, particularly in the TLO. As a  
364 result, *Csf2*<sup>-/-</sup> colons are enriched in MPs skewed towards pro-inflammatory processes,  
365 while downregulating functions attributed to anti-microbial host defense and homeostasis.



366 Collectively, these findings demonstrate that CSF2-rich TLOs constitute microanatomic  
367 niches for the homeostatic development and functional programming of MPs in the colon.

368 **CSF2-dependent Tim-4<sup>+</sup>CD4<sup>-</sup> MPs are required for proper host defense against**  
369 **enteric infections**

370 ILC3s are central for the innate immune response against attaching and effacing enteric  
371 pathogens like *Citrobacter rodentium*, the murine counterpart of human enteropathogenic  
372 *E. coli* (Song *et al.*, 2015). CSF2 has been implicated in supporting anti-microbial host  
373 defense against *C. rodentium* through the modulation of CD11c<sup>+</sup> myeloid cells (Hirata *et*  
374 *al.*, 2010). Assessment of the colonic MP composition in WT and *Csf2*<sup>-/-</sup> mice after  
375 infection with *C. rodentium* revealed a significantly altered expansion of Tim-4<sup>+</sup>CD4<sup>-</sup> MPs  
376 in the absence of CSF2 (**Fig 7A**). In contrast to previous reports using *C. rodentium*  
377 infections, CD11c<sup>+</sup>MHCII<sup>+</sup>CD64<sup>-</sup> DCs did not significantly differ in *Csf2*<sup>-/-</sup> and littermate  
378 controls post infection (**Fig S6A**). While differences in the distribution of cDC1 and cDC2  
379 were observed, these results suggest that CSF2-dependent MPs mediate efficient anti-  
380 microbial host defense (**Fig S6B**). Consequently, *Csf2*<sup>-/-</sup> mice showed greater weight loss,  
381 accompanied by higher bacterial burden and dissemination despite comparable infection  
382 efficiency (**Fig 7B and C**).

383 **Discussion**

384 Intestinal MPs are critical for gut homeostasis and host defense. Uncovering the  
385 mechanisms regulating their developmental and functional heterogeneity across the  
386 largest mucosal surface is a critical yet challenging step towards a detailed understanding  
387 of these cells during steady state and inflammation. Here, we provide new insights into  
388 the molecular and cellular interactions that govern microbiota- and host-regulated MP  
389 development and function in the colon. We demonstrate that microbe-derived ATP<sup>ex</sup> fuels

390 NLRP3-driven production of CSF2 by ILC3s. We identify TLOs as microanatomic  
391 locations for the interaction of ILC3s and monocyte-derived, CSF2-dependent MPs,  
392 representing a distinct niche for myeloid development and functional programming in the  
393 gut to support enteric anti-microbial host defense.

394 Intestinal TLOs form postnatally, or in response to chronic inflammation and colorectal  
395 cancer in a microbiota-dependent manner (Eberl and Lochner, 2009; Koscsó et al., 2020;  
396 Overacre-Delgoffe et al., 2021). Although best known for their role in T cell-independent  
397 B cell maturation, our findings indicate that TLOs also serve as an activation hub for  
398 monocyte-derived MPs (Tsuji *et al.*, 2008). While a population of TLO-located *Cxcl13*-  
399 expressing MPs support IgA-producing B cells during *Salmonella* infection, their  
400 developmental origin remains unknown (Koscsó *et al.*, 2020). We show that monocytes  
401 transition into TLO-associated, CSF2-dependent MPs to support host defense against  
402 infections. Whether monocyte-derived, TLO-associated MPs regulate adaptive immunity  
403 within TLOs in the steady state or inflammation remains an intriguing question for future  
404 investigation.

405 Collectively, our findings extend our knowledge on how the microbiota contributes to the  
406 steady state heterogeneity of intestinal MPs. In contrast to bacteria-derived metabolites  
407 like tryptophan or short-chain fatty acids, which require specialized biochemical pathways  
408 not present in all microbes, ATP is abundantly produced across all microbial kingdoms  
409 and governs the steady state activation of ILC3s. Our findings indicate that ATP<sup>ex</sup>, as a  
410 measurement for universal microbial energy metabolism, may serve as a rheostat for the  
411 control of gut MP development. The instability of ATP and expression of ecto-  
412 nucleotidases by the intestinal epithelium may be a rate limiting step in the activation of

413 ILC3s and the regulation of MP heterogeneity, opening new avenues for exploration into  
414 these interactions.

415 While ATP<sup>ex</sup>-mediated activation of the inflammasome exacerbates disease in extra-  
416 intestinal locations, it constitutes a critical element to tune immune homeostasis (Aganna  
417 *et al.*, 2002). In contrast to its pro-inflammatory role in other organs, CSF2 governs the  
418 steady-state transition of monocytes to macrophages in the colon and controls essential  
419 homeostatic functions and defense pathways across multiple gut MP subpopulations  
420 (Achuthan *et al.*, 2021). ILC3-derived CSF2 promotes survival of monocytes and shapes  
421 the metabolic program of colonic monocyte-derived MPs in TLOs, while maintaining  
422 functional specification of other gut-resident MP subpopulations. Moreover, TLO-  
423 associated MPs follow a distinct developmental trajectory compared to LP MPs diverging  
424 from Tim-4<sup>-</sup>CD4<sup>+</sup> MPs. Deficiency in *Csf2* results in the loss of TLO-associated MPs and  
425 promotes inflammatory pathways in LP MPs even if their gene expression suggests  
426 unresponsiveness to CSF2. This enrichment of inflammatory pathways in *Csf2*-deficient  
427 MPs may pose as a coping strategy to prevent infections and is of translational relevance,  
428 considering the presence of mutations in *CSF2RB* and the presence of neutralizing anti-  
429 CSF2 autoantibodies in complicated Crohn's disease (CD) (Chuang *et al.*, 2016; Han *et*  
430 *al.*, 2009). Interestingly, neutralizing anti-human CSF2 autoantibodies precede the onset  
431 of CD by several years (Mortha, 2021). This suggests that such perturbations of the  
432 steady state, microbiota-triggered, ILC3-CSF2 niche for MP development and function  
433 may raise the susceptibility of enteric infections that may possibly contribute the onset of  
434 CD (Mortha, 2021).

435 Collectively, our data identify a previously underappreciated role for microbe-derived ATP  
436 as a regulator of a CSF2-dependent tissue niche for the development of TLO-residing  
437 monocyte-derived MPs that support host defense in the healthy intestine.

#### 438 **Acknowledgments**

439 We thank all members of #theonlylabever for their support and discussion. We  
440 acknowledge support by the University of Toronto, Temerty Faculty of Medicine Flow  
441 Cytometry Core facility, the 10x Genomics staff at the Princess Margaret Genomics  
442 Centre, and the Division for Comparative Medicine. We wish to thank Dr. Juan-Carlos  
443 Zúñiga-Pflücker and Dr. Adam Gehring for critical reading of the manuscript.

444 This study was supported by an Ontario Trillium Scholarship and Vanier Canada  
445 Graduate Scholarship - NSERC (P.C.). K.B. is supported by a Canadian Institutes of  
446 Health Research (CIHR) Banting Postdoctoral Fellowship Program and L.N. by an  
447 Ontario Graduate Scholarship and a NSERC-PGS award. S.L.T. is a recipient of the Dr.  
448 Edward Ketchum Graduate Student Scholarship and the Canada Graduate Scholarships  
449 – Master’s (CGS M) award. T.M. is supported by a Canada Research Chair in NKT cell  
450 Immunobiology, a CIHR grant (PJT-175055), and a Canada Foundation for Innovation  
451 Physical Infrastructure Grant (29186). A.M. is supported by the Canadian Foundation for  
452 Innovation John R. Evans Leaders Fund, the CIHR (PJT-388337, 6210100847,  
453 6210100850) and a NSERC-Discovery Grant (RGPIN-2019-04521). A.M. is the Tier 2  
454 Canadian Research Chair in Mucosal Immunology and supported by the Tier 2 CRC-  
455 CIHR program (CRC-2021-00511).

#### 456 **Author contributions**

457 Conceptualization, P.C. and A.M.; Methodology, P.C. and A.M.; Software, P.C. and H.H.;  
458 Investigation, P.C., K.B., L.N., E.Y.C., S.L.T., H.L., A.W., M.K., T.D., Ab.Mo., and S.M.L.;  
459 Writing – Original Draft, P.C. and A.M.; Writing – Review & Editing, P.C. and A.M.;  
460 Funding Acquisition, A.M.; Resources, T.M., T.C., H.I., and S.E.; Supervision, A.M.

#### 461 **Declaration of interests**

462 The authors declare no competing interests.

463

#### 464 **Figure legends**

##### 465 **Figure 1. Developmental requirements and kinetics of colonic lamina propria MPs.**

466 (A) Representative flow cytometry analysis using (top) unbiased t-SNE dimensionality  
467 reduction of colonic CD64<sup>+</sup> CD11b<sup>+</sup> cells showing expression of common MP markers, or  
468 (bottom) Tim-4/CD4, Tim-4/CCR2, and Tim-4/MHCII classification strategies. (B) Contour  
469 plots (top) and quantification (bottom) of colonic MPs in B6, *Csf2*<sup>-/-</sup>, and *Ccr2*<sup>-/-</sup> mice. (C)  
470 CD45.1 B6 and CD45.2 *Ccr2*<sup>-/-</sup> female parabiotic pairs (top) were analyzed at 6 months  
471 (bottom left) or 1 year (bottom right) after surgery. Chimerism was quantified for colonic  
472 MP populations, blood monocytes and microglia. (D) *Ccr2*<sup>CreERT2</sup> x *Rosa26*<sup>td</sup> 3-week-old  
473 mice were fed tamoxifen-containing chow for 1 week, then assessed for loss of Tomato  
474 labeling in colonic MP populations at 0, 1, and 52 weeks post withdrawal of tamoxifen.  
475 Significance is calculated for each group comparing to previous timepoint. Data shown in  
476 (A) and (B) are representative of at least three independent experiments with at least  
477 three mice per group per experiment. Data shown in (C) and (D) are from two independent  
478 experiments. Two-way ANOVA (for (B and D)) or one-way ANOVA (for (C)) with post-hoc

479 Tukey's test was performed; \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ ; n.s., not  
480 significant.

481 **Figure 2. The development of colonic Tim-4<sup>+</sup>CD4<sup>+</sup> MPs requires an intact and**  
482 **diversified microbiota.** Colonic MP composition in (A) B6 mice across various ages, (B)  
483 B6 mice either left untreated or treated with broad-spectrum antibiotics (metronidazole,  
484 ampicillin, neomycin, streptomycin; MANS), (C) germ-free (GF) mice or GF mice  
485 conventionalized with SPF microbiota, (D) B6 mice colonized with *T. mu*, and (E) re-  
486 wilded B6 mice reconstituted with microbiota derived from pet-store mice. (F) *Ccr2*<sup>CreERT2</sup>  
487 x *Rosa26*<sup>td</sup> mice were injected with tamoxifen, and colonized with *T. mu* after 2 weeks  
488 via oral gavage. Colonic MPs were analyzed for Tomato label 3 weeks later. (G)  
489 Representative flow cytometry plots of mice in (F) with quantification of % Tomato<sup>+</sup> cells  
490 in each colonic MP compartment. Data shown are representative of at least three  
491 independent experiments with at least three mice per group per experiment. Multiple  
492 unpaired t-tests with two-stage Benjamini, Krieger, & Yekutieli FDR test was performed  
493 for (A),  $Q = 5\%$ , reporting q-values; each time point compared to previous time point.  
494 Two-way ANOVA with post-hoc Sidak's multiple comparisons test was performed for (B-  
495 E), unpaired Student's t-test was performed for each group in (G). \* $p < 0.05$ , \*\* $p < 0.01$ ,  
496 \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ ; n.s., not significant.

497 **Figure 3. Microbial ATP regulates MP composition and drives CSF2 production by**  
498 **ILC3s.** (A) Extracellular ATP levels in supernatants extracted from freshly isolated fecal  
499 pellets in SPF, MANS-treated SPF, and GF mice. (B-D) GF mice were orally gavaged  
500 with WT or  $\Delta(atpA-atpG)$  *Strr E. coli* MG1655 and analyzed 1 week later. (B)  
501 Quantifications of Ly6C<sup>+</sup> and CCR2<sup>+</sup> MPs. (C) Representative flow cytometry plots show

502 colonic monocyte and MP composition. (D) Quantifications of total ILC3s and CSF2-  
503 producing ILC3s in the colon. (E) Percentage of CSF2-producing colonic ILC3s in *Nlrp3*-  
504 <sup>-/-</sup> and *P2rx7*<sup>-/-</sup> mice with respective littermate controls. Data shown are representative of  
505 at least three independent experiments with at least three mice per group per experiment.  
506 One-way ANOVA with post-hoc Tukey's test (A-D) or Student's t-test (E) was performed;  
507 \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001; n.s., not significant.

508 **Figure 4. CSF2-producing ILC3s in TLOs induce CCR2<sup>+</sup>Tim-4<sup>-</sup>CD4<sup>-</sup> MPs.** (A)  
509 Representative live image of a colonic tertiary lymphoid organ (TLO) in  
510 *Rorc*<sup>+/<sup>EGFP</sup> *Ccr2*<sup>+/<sup>RFP</sup> mice. (B) Representative immunofluorescence images of colonic  
511 lamina propria (LP) and TLOs of *Cx3cr1*<sup>+/<sup>GFP</sup> *Ccr2*<sup>+/<sup>RFP</sup> mice stained for Tim-4 and DNA.  
512 (C) Proportion of CCR2-RFP<sup>+</sup> of CX3CR1-GFP<sup>+</sup> cells based on CellProfiler quantification  
513 of images in each colonic LP (CLP) region and TLOs, as indicated. (D) Colonic MP  
514 composition in adult sex-matched littermate mice as indicated. (E) 10<sup>4</sup> FACS-sorted small  
515 intestinal ILC3s from either WT or *Csf2*<sup>-/-</sup> mice were adoptively transferred into *Rag2*<sup>-/<sup>Il2r</sup>  
516 <sup>-/-</sup> mice, and recipients were analyzed at 6 weeks (left). Quantifications (right) of colonic  
517 MP populations post-transfer, as indicated. Data shown are representative of at least  
518 three independent experiments with at least three mice per group per experiment. One-  
519 way ANOVA with post-hoc Tukey's test was performed for (C) and (E); \*p < 0.05, \*\*p <  
520 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001; n.s., not significant.</sup></sup></sup></sup></sup>

521 **Figure 5. scRNA-Seq analysis of colonic LP MPs inside and outside of TLOs reveal**  
522 **further heterogeneity and preferential localizations.** (A) Representative live image of  
523 a colonic tertiary lymphoid organ (TLO) in *Rorc*<sup>+/<sup>EGFP</sup> *Ccr2*<sup>+/<sup>RFP</sup> mice. (B) Experimental  
524 scheme for scRNA-Seq set-up. (C) UMAP projection of the combined analysis of LP<sup>WT</sup>,</sup></sup>

525 TLO<sup>WT</sup>, LP<sup>Csf2<sup>-/-</sup></sup>, and TLO<sup>Csf2<sup>-/-</sup></sup> subsetted and re-clustered for MPs and monocytes  
526 visualized together. (D) UMAP projection of MPs/Mos of LP<sup>WT</sup> and TLO<sup>WT</sup> (left) with  
527 quantification of the relative abundance of each cluster for each sample (right). (E)  
528 Heatmap depicting the top 30 DEGs for each cluster (log<sub>2</sub>FC threshold = 0.25, min.pct =  
529 0.25, adjusted p < 0.05), downsampled to 50 cells for visualization. The number of DEGs  
530 in each cluster is shown (bottom). (F) Feature plots illustrating expression of subset-  
531 defining genes. (G) Pathway enrichment analysis (gProfiler, Gene Ontology (GO)  
532 biological processes) using DEGs for each cluster. (H) UMAP dimensionality reduction  
533 using Monocle 3 was performed and visualized with overlaid Seurat annotations from (D)  
534 (left). Trajectory analysis was performed using Monocle 3 as indicated by solid black lines  
535 (middle, right). Changes in expression of subset-defining genes were visualized in  
536 conjunction with trajectory analysis (middle), and pseudotime analysis was performed and  
537 visualized using Monocle 3 (right).

538 **Figure 6. CSF2 deficiency results in a loss of TLO MPs and functional dysregulation**  
539 **of colonic MPs.** (A) Dot plot showing expression of *Csf1r*, *Csf2ra*, and *Csf2rb* in each  
540 cluster from the merged data. Color denotes expression level, and dot size indicates  
541 percent of cells within the cluster expressing the gene, as indicated. (B) UMAP projection  
542 of MPs/Mos of each sample (left) with quantification of the relative abundance of each  
543 cluster for each sample (right). (C) Pathway enrichment analysis (gProfiler, Gene  
544 Ontology (GO) biological processes) using DEGs differentially regulated between WT  
545 versus *Csf2<sup>-/-</sup>* in each region (LP, left; TLO, right) for selected clusters, as indicated.  
546 Negative values of -log<sub>10</sub> of adjusted p-value indicate upregulation in *Csf2<sup>-/-</sup>*, positive  
547 values indicate upregulation in WT.



548 **Figure 7. Host defense against *C. rodentium* requires CSF2-dependent Tim-4<sup>+</sup>CD4<sup>+</sup>**  
549 **MPs.** Groups of age- and sex-matched mice were infected with *C. rodentium* for 2 weeks.  
550 (A) Quantification of relative abundance of colonic MP populations. (B) Body weight was  
551 tracked daily during the course of infection. (C) Quantification of *C. rodentium* in the colon,  
552 feces, and liver at end point. Data shown is representative of at least three independent  
553 experiments with at least three mice per group per experiment. Two-way ANOVA with  
554 post-hoc Tukey's multiple comparison test was performed for (A), mixed-effects analysis  
555 was performed with post-hoc Sidak's multiple comparisons test for (B), and unpaired  
556 Student's t test was performed for (C); \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001; n.s., not  
557 significant.

558 **Supplemental Figure 1. Macrophage classification and developmental**  
559 **phenotyping.** (A) Gating strategy for intestinal MPs. (B) Representative flow cytometry  
560 plots of colonic and small intestinal MPs using the Tim-4/CD4 classification. (C)  
561 Representative flow cytometry plots of colonic MPs in sex-matched littermate WT, *Csf2*<sup>-/-</sup>  
562 , and *Ccr2*<sup>-/-</sup> mice showing the monocyte waterfall (top) and Tim-4/CCR2 (bottom) gating  
563 strategies. (D) Representative flow cytometry plots showing CD45.1 chimerism of colonic  
564 MP populations in 6-month parabiotic mice.

565 **Supplemental Figure 2. ATPase-deficient *E. coli* generate lower levels of ATP.** (A-  
566 E) *E. coli* MG1655 wild-type, ATPase-deficient ( $\Delta(atpA-atpG)$ ), and nitrate reductase-  
567 deficient ( $\Delta narG \Delta narZ \Delta(napD-napA)$ ) mutant strains were cultured *in vitro* overnight,  
568 then transferred into fresh media, and subsequently evaluated at the indicated timepoints.  
569 (A) Growth curve of *E. coli* MG1655 strains measured by OD<sub>600</sub> as indicated. (B)  
570 Supernatant ATP levels (ATP<sup>ex</sup>) were quantified using the Promega ENLITEN ATP Assay

571 as per the manufacturer's instructions. (C) Intracellular ATP (ATP<sup>int</sup>) can be quantified by  
572 measuring fluorescence intensity of the ATeam 3.10 plasmid. (D) Representative  
573 histograms showing fluorescence intensity of the ATeam 3.10 plasmid in each *E. coli*  
574 strain at the specified timepoints measured by flow cytometry. (E) Quantification of the  
575 median fluorescence intensity of (D). (F-G) *E. coli* MG1655 wild-type and  $\Delta(atpA-atpG)$   
576 mutant were isolated and assessed from 1-week-colonized germ-free mice. (F) CFUs of  
577 each *E. coli* strain were quantified in the feces of colonized mice. (G) Each *E. coli* strain  
578 was isolated from fecal samples of respective colonized mice and assessed for levels of  
579 ATP<sup>int</sup> by flow cytometry; showing median fluorescence intensity (MFI). Data shown are  
580 representative of at least three independent experiments with at least three mice per  
581 group per experiment. Unpaired Student's t test was performed for (F) and (G); \*p < 0.05;  
582 n.s., not significant.

583 **Supplemental Figure 3. Sorting strategy and post-transfer verification of ILC3s for**  
584 **adoptive transfer experiment.** (A) Representative sorting strategy of SI *Rorc*<sup>+EGFP</sup>  
585 ILC3s (WT or *Csf2*<sup>-/-</sup>) for adoptive transfer. (B) Relative abundance of colonic ILC3s (Lin<sup>-</sup>  
586 ROR $\gamma$ t-GFP<sup>+</sup>) out of CD45<sup>+</sup> cells to validate the reconstitution of *Rorc*<sup>+EGFP</sup> ILC3s in *Rag2*<sup>-/-</sup>  
587 *I12r*<sup>-/-</sup> recipients at 6 weeks post-transfer. One-way ANOVA with Tukey's test was  
588 performed; \*p < 0.05.

589 **Supplemental Figure 4. Gene expression profiling of macrophage clusters by**  
590 **scRNA-Seq.** (A) UMAP dimensionality reduction and combined analysis of all datasets,  
591 representing 15,369 cells that have passed QC filtering; colored based on sample identity  
592 (left) or clusters (right). Cell populations identified and annotated based on DEG  
593 expression analysis of each cluster. (B) Heatmap of the top 30 genes per cluster,

594 downsampled to 50 cells per cluster for visualization, based on DEG analysis across  
595 clusters (logFC threshold = 0.25, min.pct = 0.25, adj p val < 0.05). (C) Feature plots  
596 depicting gene expression patterns of MP/DC markers used to subset MP/Mo clusters  
597 and exclude DC clusters. (D) Feature plots confirming expression of MP markers in  
598 subsetted and re-clustered MP/Mos. (E) KEGG pathway enrichment analysis (gProfiler)  
599 using DEGs for each cluster.

600 **Supplemental Figure 5. Differential analysis of WT versus *Csf2*<sup>-/-</sup> MP**  
601 **subpopulations.** Quantification of apoptotic cells within each colonic MP population in  
602 sex-matched littermate WT versus *Csf2*<sup>-/-</sup> mice by ApoTracker staining, as indicated.  
603 Unpaired Student's t test was performed; \*p < 0.05; n.s., not significant.

604 **Supplemental Figure 6. DC phenotyping during *C. rodentium* infection.** Groups of  
605 age- and sex-matched mice were infected with *C. rodentium* for 2 weeks. (A)  
606 Quantification of CD11c<sup>+</sup>MHCII<sup>+</sup>CD64<sup>-</sup> DCs. (B) Relative abundance of each DC subset.  
607 Unpaired Student's t test was performed; \*p < 0.05.

608

## 609 **STAR Methods**

### 610 **Key resources table**

611 For surface staining, the following anti-mouse Abs were used: TCR $\beta$  (H57-597;  
612 eBioscience), CD4 (GK1.5; BioLegend), CD45 (30-F11; BioLegend), CD218a (IL-18Ra)  
613 (P3TUNYA; eBioscience), ST2 (RMST2-2; eBioscience), CD11b (M1/70; BioLegend),  
614 Ly6c (HK1.4; eBioscience), CD64 (X54-5/7.1; BioLegend), and MHCII (I-A/I-E)  
615 (M5/114.15.2; eBioscience). Intracellular markers include anti-mouse IFN- $\gamma$  (XMG1.2;

616 eBioscience), TNF $\alpha$  (MP6-XT22; eBioscience), IL-10 (JESS-16E3; BioLegend), IL-17A  
 617 (TC11-18H10.1; BioLegend), and FOXP3 (MF-14; BioLegend). CD4<sup>+</sup> T cells were gated  
 618 as Live CD45<sup>+</sup> TCR $\beta$ <sup>+</sup> CD4<sup>+</sup>. Immature macrophages were gated as Live CD45<sup>+</sup> CD64<sup>+</sup>  
 619 CD11b<sup>+</sup> Ly6c<sup>hi</sup> MHCII<sup>lo</sup>.

620

REAGENT RESOURCE	or	SOURCE	IDENTIFIER
Antibodies			
CD45 (clone 30-F11)		BioLegend	Cat #103116
CD45.1 (clone A20)		BioLegend	Cat #110724
CD45.2 (clone 104)		BioLegend	Cat #109824
CD4 (clone GK1.5)		BioLegend	Cat #100406
CD11b (clone M1/70)		BioLegend	Cat #101216
Ly6c (clone HK1.4)		BioLegend	Cat #128012
CD64 (clone X54-5/7.1)		BioLegend	Cat #139311
MHCII (I-A/I-E) (clone M5/114.15.2)		eBioscience	Cat #107620
CCR2 (clone SA203G11)		BioLegend	Cat #150610
Tim-4 (clone RMT4-54)		BioLegend	Cat #130008
ROR $\gamma$ t (clone B2D)		eBioscience	Cat #53-981-82
TCR $\beta$ (clone H57-597)		eBioscience	Cat #45-5961-82
TCR $\gamma$ / $\delta$ (clone eBioGL3)		eBioscience	Cat #46-5711-82
B220			
CD3 $\epsilon$ (clone 145-2C11)		BioLegend	Cat #100328
CSF2 (clone MP1-22E9)		BioLegend	Cat #505406
CD115 (CSF1R) (clone AFS98)		BioLegend	Cat #135510
Ly6g (clone 1A8)		BioLegend	Cat #127612
Fc block (CD16/CD32)		eBioscience	Cat #14-9161-73
Fixable Viability Dye eFluor™ 506		eBioscience	Cat #65-0866-18
ApoTracker™ Green		BioLegend	Cat #427402
Experimental models: Organisms/Strains/Plasmids			
B6.129S-Csf2 <sup>tm1Mlg/J</sup> (Csf2 <sup>-/-</sup> )		The Jackson Laboratory	Strain #026812
B6.129S4-Ccr2 <sup>tm1Ifc/J</sup> (Ccr2 <sup>-/-</sup> )		The Jackson Laboratory	Strain #004999
B6.129P2(Cg)-Cx3cr1 <sup>tm1Litt/J</sup> (Cx3cr1 <sup>gfp</sup> )		The Jackson Laboratory	Strain #005582

B6.129(Cg)- <i>Ccr2</i> <sup>tm2.1<sup>ffc</sup>/J</sup> ( <i>Ccr2</i> <sup>rfp</sup> )	The Laboratory	Jackson	Strain #017586
B6.129P2(C)- <i>Cx3cr1</i> <sup>tm2.1(cre/ERT2)Jung/J</sup> ( <i>Cx3cr1</i> <sup>CreERT2</sup> )	The Laboratory	Jackson	Strain #020940
B6.Cg- <i>Gt(ROSA)26Sor</i> <sup>tm14(CAG- tdTomato)Hze/J</sup> ( <i>Rosa26</i> <sup>Td</sup> )	The Laboratory	Jackson	Strain #007914
B6.129P2(Cg)- <i>Rorc</i> <sup>tm2Litt/J</sup> ( <i>Rorc</i> <sup>gfp</sup> )	The Laboratory	Jackson	Strain #007572
B6.Cg- <i>Rag2</i> <sup>tm1.1Cgn/J</sup>	The Laboratory	Jackson	Strain #008449
B6.129S6- <i>Nlrp3</i> <sup>tm1Bhk/J</sup> ( <i>Nlrp3</i> <sup>-/-</sup> )	The Laboratory	Jackson	Strain #021302
B6.129P2-P2rx7 <sup>tm1Gab/J</sup> ( <i>P2xr7</i> <sup>-/-</sup> )	The Laboratory	Jackson	Strain #005576
Pet store mice	Hill Oak Ranch, Ltd.		
<i>Citrobacter rodentium</i> ICC180	Dana	Philpott	(University of Toronto)
<i>E. coli</i> MG1655 <i>Strr</i>	Tyrell (Oklahoma University)	Conway State	
<i>E. coli</i> MG1655 <i>Strr</i> $\Delta(atpA-atpG)$	Tyrell (Oklahoma University)	Conway State	
<i>E. coli</i> MG1655 <i>Strr</i> $\Delta narG$ $\Delta narZ \Delta(napD-napA)$	Tyrell (Oklahoma University)	Conway State	
<i>pRSET-AT3.10</i>	Hiromi Imamura (Kyoto University)		
Software and algorithms			
FlowJo v.10	FlowJo, LLC		<a href="https://www.flowjo.com/">https://www.flowjo.com/</a>
Zen Pro	Zeiss		
CellProfiler	Broad Institute		<a href="https://cellprofiler.org/">https://cellprofiler.org/</a>
GraphPad Prism v.8.0	GraphPad		
CellRanger	10x Genomics		
Seurat v.4.0	(Hao et al., 2021)		<a href="https://satijalab.org/seurat/">https://satijalab.org/seurat/</a>
R v.4.1.2	The R Foundation		<a href="https://www.r-project.org">https://www.r-project.org</a>
SCTransform	(Hafemeister and Satija, 2019)		
gProfiler			<a href="https://biit.cs.ut.ee/gprofiler/gost">https://biit.cs.ut.ee/gprofiler/gost</a>
Monocle 3			<a href="https://cole-trapnell-lab.github.io/monocle3/">https://cole-trapnell- lab.github.io/monocle3/</a>

621

622

623 **Resource availability**

624 Single-cell RNA-seq data additional information required to reanalyze the data reported  
625 in this paper is available from the lead contact upon request.

626 **Experimental model and subject details**

627 **Mice**

628 All mice were purchased from Jackson Laboratory and subsequently bred in-house under  
629 specific pathogen-free conditions at the University of Toronto, Division of Comparative  
630 Medicine. Strains and stock numbers are listed in the Key resources table. Unless  
631 otherwise stated, all experiments were conducted using 8-10-week-old age- and sex-  
632 matched littermates. Germ-free animals were maintained in the gnotobiotic facility at the  
633 University of Toronto, Division of Comparative Medicine. To obtain re-wilded mice, pet  
634 store mice were purchased from High Oak Ranch Ltd. (Baden, ON) and bred in our mouse  
635 facility in a containment room (bioBUBBLE Inc, Fort Collins, CO). C57Bl/6 (B6) pups were  
636 co-housed with pet store pups from 3 to 7 weeks of age, separated and subsequently  
637 bred. B6 pregnant dams were gavaged with cecal content from pet store female mice 2  
638 to 3 days prior to delivery. The pups were used to establish a re-wilded colony for  
639 experiments. All experiments were approved by the Faculty of Medicine and Pharmacy  
640 Animal Care Committee at the University of Toronto (animal use protocols 20011887 and  
641 20012454 to TM and 20012400 to AM).

642 **Microbes**

643 All *E. coli* MG1655 strains were provided by Dr. Tyrell Conway (Oklahoma State  
644 University). *C. rodentium* ICC180 was a gift from Dr. Dana Philpott (University of Toronto).  
645 The plasmid encoding the ATP biosensors (pRSET-AT3.10) were a kind gift from Dr.  
646 Hiromi Imamura (Kyoto University).

647 **Method details**

648 **Purification and colonization of *Tritrichomonas musculus***

649 Cecal contents of *T. mu*<sup>+</sup> mice were collected, resuspended in PBS, filtered through a 70  
650 µm cell strainer, and spun for 10 min at 600 x *g*. The resulting pellet was put through a  
651 40/80% Percoll gradient centrifugation. The *T. mu*-enriched interphase was collected.  
652 Protozoa were then resuspended in PBS and double sorted into PBS based on size,  
653 granularity, and violet autofluorescence on a FACSAria II. Two million *T. mu* were orally  
654 gavaged into mice immediately after the sort.

655 ***C. rodentium* infection and pathological assessment**

656 Groups of age- and sex-matched littermates were infected with *C. rodentium* ICC180 (~2  
657 x 10<sup>8</sup> CFUs) by oral gavage as previously described (Bouladoux et al., 2017). Mice were  
658 weighed daily to monitor disease progression and euthanized at 2 w p.i. Colons were  
659 harvested for lamina propria leukocyte isolation and downstream analysis. Colony  
660 forming units (CFUs) of *C. rodentium* in feces, colon, and liver were measured on  
661 MacConkey agar plates containing 100 µg/mL kanamycin.

662 **Generation of *E. coli* MG1655 ATeam strains**

663 ATeam plasmid was isolated from *E. coli* ATeam3.10 using the Monarch<sup>®</sup> Plasmid DNA  
664 Miniprep Kit (New England Biolabs) as per the manufacturer's protocol. *E. coli* MG1655  
665 *Strr*, *E. coli* MG1655 *Strr* Δ(*atpA-atpG*), and *E. coli* MG1655 *Strr* Δ*narG* Δ*narZ* Δ(*napD-*  
666 *napA*) strains were treated with calcium chloride to make them chemically competent for  
667 plasmid DNA uptake. Transformation was performed on these chemically competent cells  
668 to transfer the ATeam plasmid, following New England Biolabs' High Efficiency  
669 Transformation Protocol.

670 **Colonization of germ-free mice with *E. coli* strains**

671 Groups of age- and sex-matched littermate germ-free mice were orally gavaged with  $\sim 10^3$   
672 CFU of *E. coli* MG1655 WT or *E. coli* MG1655  $\Delta narG \Delta narZ \Delta(napD-napA)$ , or  $\sim 10^4$  CFU  
673 of *E. coli* MG1655 *Strr*  $\Delta(atpA-atpG)$ . Differences in starting CFU accounted for the slower  
674 growth rate of *E. coli*  $\Delta(atpA-atpG)$  to ensure equal colonization efficiency at time of  
675 analysis. Mice were analyzed 1 w later. Fecal pellets were collected both prior to gavage  
676 and at time of harvest to confirm colonization.

677 **Antibiotics treatment**

678 Mice were treated with metronidazole (0.5 g/L), ampicillin (1 g/L), neomycin (1 g/L), and  
679 streptomycin (1 g/L) *ad libitum* for 2 weeks via drinking water. Water containing antibiotics  
680 was exchanged every 3 days.

681 **Isolation of intestinal lamina propria leukocytes**

682 Colonic or small intestinal (SI) lamina propria (LP) cells were isolated as previously  
683 described (Chiaranunt et al., 2020). Briefly, intestines were washed in HBSS plus 5 mM  
684 EDTA and 10 mM HEPES to strip the epithelium. Tissues were then minced and shaken  
685 at 37°C for 20 min in digestion buffer (HBSS with calcium and magnesium, supplemented  
686 with 10 mM HEPES, 4% FBS, penicillin-streptomycin (Sigma Aldrich), 0.5 mg/mL DNase  
687 I (Sigma Aldrich), and 0.5 mg/mL Collagenase (Sigma Aldrich)). Supernatants were  
688 collected and enriched for leukocytes using a 40/80% Percoll gradient, after which cells  
689 are ready for downstream use.

690 **Flow cytometry**

691 For surface staining, after isolation of intestinal LP leukocytes, cells were resuspended in  
692 FACS buffer (PBS w/o  $Ca^{2+}$   $Mg^{2+}$  supplemented with 2% heat inactivated FBS and 5 mM



693 EDTA) and then incubated on ice for 20 min with Fc block (CD16/CD32; eBioscience),  
694 surface marker antibodies, and Fixable Viability Dye eFluor™ 506 (eBioscience). For flow  
695 cytometric detection of apoptotic cells, ApoTracker™ Green was added in conjunction to  
696 surface stains, and samples were instead incubated at room temperature for 20 min as  
697 per manufacturer's protocol.

698 For intracellular staining, cells were first stimulated for 4 h at 37°C in R-10+ media  
699 supplemented with protein transport inhibitor cocktail containing Brefeldin A and  
700 Monensin (eBioscience). Cells were then washed and resuspended in FACS buffer and  
701 incubated on ice for 20 min with Fc block (CD16/CD32; eBioscience), surface marker  
702 antibodies, and Fixable Viability Dye eFluor™ 506 (eBioscience). Cells were fixed and  
703 permeabilized using the BD Cytofix/Cytoperm Kit, followed by cytokine stains, then re-  
704 fixed and permeabilized using the eBioscience Foxp3/Transcription Factor Staining  
705 Buffer Set, followed by transcription factor stains.

706 Samples were analyzed on an LSR Fortessa X-20 (BD) with subsequent cytometric data  
707 analysis using FlowJo. All antibodies used in this study are listed in the Key resources  
708 table.

### 709 ***In vitro E. coli* culture and ATP measurement**

710 Each *E. coli* strain was grown overnight at 37°C with shaking in LB broth containing 50  
711 µg/mL streptomycin. The next day, OD600 was measured for each culture, and aliquots  
712 were taken for extracellular ATP (ATP<sup>ex</sup>) and intracellular ATP (ATP<sup>int</sup>) quantification.  
713 Each sample was then aliquoted into fresh media (LB with 50 µg/mL streptomycin) and  
714 placed in the shaking incubator. An aliquot was removed every 2 h for OD600  
715 measurement and ATP quantification. For ATP measurements, aliquots were spun down

716 at 3,000 x *g*. Supernatants were analyzed for ATP<sup>ex</sup> using the ENLITEN ATP Assay  
717 System Bioluminescence Detection Kit (Promega) according to the manufacturer's  
718 instructions. Pellets containing *E. coli* were resuspended and analyzed on the BD  
719 LSRFortessa for ATP<sup>int</sup>.

### 720 **Luminal ATP measurement**

721 Fecal samples were collected, homogenized in PBS plus 0.01% NaN<sub>3</sub> using the Omni  
722 Bead Ruptor 24, and centrifuged twice (800 x *g* followed by 10000 x *g*) to remove debris  
723 and microbes. Supernatants were filtered through a 0.2 μm filter and Amicon Ultra-0.5  
724 centrifugal filter unit (Millipore Sigma), then analyzed for ATP levels using the ENLITEN  
725 ATP Assay System Bioluminescence Detection Kit (Promega) according to the  
726 manufacturer's instructions.

### 727 **Parabiosis**

728 The lateral aspects of CD45.1 mice (Jackson, #002014; left, donor) and CD45.2 *Ccr2*<sup>-/-</sup>  
729 mice (Jackson, #004999; right, recipient) were shaved, and matching skin incisions were  
730 made from behind the ear to the tail of each mouse, as previously described (Dick *et al.*,  
731 2022). The subcutaneous fascia was dissected to create ~0.5 cm of free skin. The  
732 olecranon and knee joints were attached by a mono-nylon 5.0 suture (Ethicon) and the  
733 dorsal and ventral skins were attached by continuous suture. Animals recovered with an  
734 immediate 0.1mg/kg injection of buprenorphine given subcutaneously. Subcutaneous  
735 injections of saline and buprenorphine were given daily for 1 week after the surgery and  
736 3% neomycin antibiotics for 2 weeks. Four-week-old mice were joined for 6 months to 1  
737 year. The CD45.2 recipient mice were analyzed for level of chimerism of CD45.1<sup>+</sup> cells.

### 738 **Fate-mapping**

739 Tamoxifen was dissolved in corn oil at a concentration of 20 mg/mL by shaking for at least  
740 an hour at 55°C and then brought to room temperature. Dissolved tamoxifen was injected  
741 intraperitoneally to *Cx3cr1<sup>CreERT2</sup> x Rosa26<sup>Td</sup>* mice at 1 mg/kg body weight at day -2 and  
742 day 0 prior to the start of the experiment. For *Ccr2<sup>CreERT2</sup> x Rosa26<sup>Td</sup>* mice, mice were fed  
743 tamoxifen-containing chow (Envigo) for 10 days and then switched back to normal chow  
744 during the chase period.

### 745 **Immunofluorescence**

746 Colonic tissues were flushed with 4% formaldehyde, then fixed with 2% formaldehyde  
747 10% sucrose for 1.5 h on ice, followed by an overnight 30% sucrose gradient. Tissues  
748 were subsequently embedded in OCT medium (ThermoFisher), flash frozen in 2-  
749 methylbutane, and sectioned in 7 µm slices. Sections were blocked and permeabilized  
750 for 1 h with blocking/permeabilization buffer (10% BSA, 0.01% Triton X in PBS), washed  
751 with PBS, and subsequently stained with antibodies diluted in blocking/permeabilization  
752 buffer for 1 h at RT. Sections were mounted with Fluoroshield with DAPI medium (Sigma  
753 Aldrich). Slides were imaged at 20X using a Zeiss Axio Imager Z1 and quantified with  
754 CellProfiler software (Broad Institute)(McQuin et al., 2018).

### 755 **Adoptive transfer**

756 Leukocytes were isolated from the small intestines of CD45.1/2 *Rorc<sup>+EGFP</sup>* or CD45.1/2  
757 *Rorc<sup>+EGFP</sup> x Csf2<sup>-/-</sup>* littermate mice as described above and FACS-sorted for ILC3s using  
758 the BD FACSAria II based on Lin<sup>-</sup> and GFP<sup>+</sup> expression. Cells were sorted into R-10+  
759 media, checked for purity, then washed with sterile PBS. 10<sup>4</sup> purified ILC3s were injected  
760 intravenously into age- and sex-matched *Rag2<sup>-/-</sup>Il2rg<sup>-/-</sup>* recipient co-housed littermate  
761 mice via the retroorbital route. Recipient mice were analyzed 6 weeks later.

762 **Single-cell RNA sequencing**

763 **Sample preparation**

764 Colons (n=5 per group) from age- and sex-matched *Cx3cr1<sup>GFP/+</sup>Ccr2<sup>RFP/+</sup>* WT versus  
765 *Csf2<sup>-/-</sup>* littermate mice were isolated and stripped of epithelium as detailed above, then  
766 placed under a Zeiss AxioZoom.V16 fluorescent microscope for live imaging. Solitary  
767 isolated lymphoid tissues (SILTs) were identified based on GFP and RFP expression and  
768 isolated using a 1.25 mm biopsy puncher. SILTs and remaining punched out colons were  
769 pooled and placed separately into R-10+ media. Samples were digested and enriched for  
770 leukocytes as detailed above. Samples were then enriched for CD11b<sup>+</sup> cells using the  
771 EasySep™ Mouse CD11b Positive Selection Kit II (StemCell Technologies) as per the  
772 manufacturer's protocol. Purified single cell suspensions (>90% purity) were  
773 resuspended in R-10+ media for 10x Genomics single-cell RNA sequencing.

774 **Library preparation, sequencing, pre-processing, and quality control**

775 Single cell suspensions were prepared and loaded onto the v3 10x Chromium for the  
776 generation of sequencing libraries and processing as described by 10x Genomics.  
777 CellRanger (10x Genomics) was used to pre-process sequenced cells, align reads, and  
778 generate expression matrices. Seurat (v.4.0) was used for all pre-processing, filtering,  
779 and downstream analyses (Hao *et al.*, 2021). Low-quality cells expressing fewer than 200  
780 genes were removed. Doublets and dead cells were excluded based on high number of  
781 genes (>6000) and high percentage (>9%) of transcripts mapping to mitochondrial genes,  
782 respectively. Cells with high percentage (>20%) of transcripts mapping to dissociation-  
783 associated genes (DAGs), as previously described, were also removed (O'Flanagan *et*  
784 *al.*, 2019).

## 785 **Normalization, dimensionality reduction, clustering, and cell annotation**

786 To remove technical variation, data was normalized using SCTransform, which utilizes  
787 negative binomial regression to normalize the data, find variable features, and scale the  
788 data (Hafemeister and Satija, 2019). The variance-stabilizing transformation (vst) method  
789 in SCTransform was used to select 3000 highly variable features. Mitochondrial gene  
790 percentage and number of counts (nCount\_RNA) were regressed out. Dimensionality  
791 reduction was performed using principal component analysis (PCA), and an elbow plot  
792 was used to determine the number of statistically significant PCs for subsequent  
793 clustering. FindNeighbors and FindClusters functions were used to perform graph-based  
794 clustering. Non-linear dimensionality reduction and visualization was performed using the  
795 Uniform Manifold Approximation and Projection (UMAP) method. Clusters were identified  
796 and annotated based on differential gene expression testing using the Wilcoxon Rank  
797 Sum Test, with the following parameters in the FindAllMarkers function: min.pct=0.25,  
798 logFC threshold=0.25, adjusted p-value<0.05. For heatmaps, each cluster was  
799 downsampled to 50 cells for visualization, showing the top 30 differentially expressed  
800 genes of each cluster.

801 Macrophage and monocyte clusters were identified based on expression of MP markers  
802 (*C1qa*, *Csf1r*, *Cx3cr1*, and *Adgre1*) and absence of DC markers (*Flt3*, *Dpp4*, *Zbtb46*).  
803 These clusters were further subsetted (using the “subset” function), and normalization,  
804 dimensionality reduction, and clustering were re-performed as described above to obtain  
805 specific MP and monocyte clusters. Clusters were identified, annotated, and visualized  
806 as described above.

## 807 **Differential gene expression**

808 To compare gene expression of MPs between wild-type (WT) versus *Csf2<sup>-/-</sup>* (KO) LP and  
809 TLO, the “subset” function was used to separate each cluster from each dataset. The  
810 FindMarkers function (min.pct = 0.25, logFC threshold = 0.25, adjusted p value < 0.05)  
811 was used to compute differentially upregulated and downregulated genes for each cluster  
812 in KO relative to WT of each region (e.g. KO LP relative to WT LP, KO TLO relative to  
813 WT TLO). Resulting genes were used for subsequent pathway enrichment analysis, as  
814 indicated.

### 815 **Pathway enrichment analysis**

816 gProfiler functional profiling (<https://biit.cs.ut.ee/gprofiler/gost>) was used to measure over-  
817 representation of target gene list against the annotated gene database of Gene Ontology  
818 (GO; <http://www.geneontology.org>). Enriched biological processes of GO (BP, 2019) and  
819 enriched KEGG pathways were identified and ordered based on enrichment scores (-  
820 log<sub>10</sub> of the adjusted p value).

### 821 **Single-cell trajectory analysis**

822 The R package Monocle 3 was used to assess cell trajectories (Cao et al., 2019; Qiu et  
823 al., 2017; Trapnell et al., 2014). Data previously analyzed with Seurat (v.4.0), as  
824 described above, were imported into Monocle 3 for re-clustering. Briefly, highly variable  
825 genes imported from the Seurat analysis were used for PCA dimensionality reduction,  
826 followed by UMAP non-linear dimensionality reduction and subsequent clustering using  
827 Leidan community detection (<https://arxiv.org/abs/1802.03426>). The number of Monocle  
828 clusters were similar to Seurat clusters. This method also generates ‘partitions’  
829 representing groups corresponding to separate trajectories. Cell trajectory was assessed  
830 using the “learn\_graph” function, which uses the DDRTree method to learn tree-like

831 trajectories and further reduce dimensionality. Data were visualized with UMAP  
832 embeddings and trajectories derived within Monocle and overlaid with Seurat clusters.

### 833 **Quantification and statistical analysis**

834 Statistical analysis of non-sequencing data was performed with the GraphPad Prism  
835 software (GraphPad), with statistical tests detailed in the figure legends. All data are  
836 shown as mean  $\pm$  SEM.

837

### 838 **References**

839 Achuthan, A.A., Lee, K.M.C., and Hamilton, J.A. (2021). Targeting GM-CSF in  
840 inflammatory and autoimmune disorders. *Semin Immunol* 54, 101523.  
841 10.1016/j.smim.2021.101523.

842 Aganna, E., Martinon, F., Hawkins, P.N., Ross, J.B., Swan, D.C., Booth, D.R., Lachmann,  
843 H.J., Bybee, A., Gaudet, R., Woo, P., et al. (2002). Association of mutations in the  
844 NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold  
845 sensitivity, sensorineural deafness, and AA amyloidosis. *Arthritis Rheum* 46, 2445-2452.  
846 10.1002/art.10509.

847 Amorim, A., De Feo, D., Friebel, E., Ingelfinger, F., Anderfuhren, C.D., Krishnarajah, S.,  
848 Andreadou, M., Welsh, C.A., Liu, Z., Ginhoux, F., et al. (2022). IFN $\gamma$  and GM-CSF  
849 control complementary differentiation programs in the monocyte-to-phagocyte transition  
850 during neuroinflammation. *Nat Immunol* 23, 217-228. 10.1038/s41590-021-01117-7.

851 Atarashi, K., Nishimura, J., Shima, T., Umesaki, Y., Yamamoto, M., Onoue, M., Yagita,  
852 H., Ishii, N., Evans, R., Honda, K., and Takeda, K. (2008). ATP drives lamina propria  
853 T(H)17 cell differentiation. *Nature* 455, 808-812. 10.1038/nature07240.

854 Bain, C.C., Bravo-Blas, A., Scott, C.L., Perdiguero, E.G., Geissmann, F., Henri, S.,  
855 Malissen, B., Osborne, L.C., Artis, D., and Mowat, A.M. (2014). Constant replenishment  
856 from circulating monocytes maintains the macrophage pool in the intestine of adult mice.  
857 *Nat Immunol* 15, 929-937. 10.1038/ni.2967.

858 Blaut, M., and Clavel, T. (2007). Metabolic diversity of the intestinal microbiota:  
859 implications for health and disease. *J Nutr* 137, 751S-755S. 10.1093/jn/137.3.751S.

860 Bleriot, C., Chakarov, S., and Ginhoux, F. (2020). Determinants of Resident Tissue  
861 Macrophage Identity and Function. *Immunity* 52, 957-970.  
862 10.1016/j.immuni.2020.05.014.

863 Bouladoux, N., Harrison, O.J., and Belkaid, Y. (2017). The Mouse Model of Infection with  
864 *Citrobacter rodentium*. *Curr Protoc Immunol* 119, 19 15 11-19 15 25. 10.1002/cpim.34.

865 Cao, J., Spielmann, M., Qiu, X., Huang, X., Ibrahim, D.M., Hill, A.J., Zhang, F., Mundlos,  
866 S., Christiansen, L., Steemers, F.J., et al. (2019). The single-cell transcriptional landscape  
867 of mammalian organogenesis. *Nature* 566, 496-502. 10.1038/s41586-019-0969-x.

868 Chang, P.V., Hao, L., Offermanns, S., and Medzhitov, R. (2014). The microbial metabolite  
869 butyrate regulates intestinal macrophage function via histone deacetylase inhibition. *Proc*  
870 *Natl Acad Sci U S A* 111, 2247-2252. 10.1073/pnas.1322269111.

871 Chiaranunt, P., Burrows, K., Ngai, L., Cao, E.Y., Liang, H., Tai, S.L., Streutker, C.J.,  
872 Girardin, S.E., and Mortha, A. (2022). NLRP1B and NLRP3 Control the Host Response



873 following Colonization with the Commensal Protist *Tritrichomonas musculus*. *J Immunol.*  
874 10.4049/jimmunol.2100802.

875 Chiaranunt, P., Burrows, K., Ngai, L., and Mortha, A. (2020). Isolation of mononuclear  
876 phagocytes from the mouse gut. *Methods Enzymol* 632, 67-90.  
877 10.1016/bs.mie.2019.10.004.

878 Chiaranunt, P., Tai, S.L., Ngai, L., and Mortha, A. (2021). Beyond Immunity:  
879 Underappreciated Functions of Intestinal Macrophages. *Front Immunol* 12, 749708.  
880 10.3389/fimmu.2021.749708.

881 Chuang, L.S., Villaverde, N., Hui, K.Y., Mortha, A., Rahman, A., Levine, A.P., Haritunians,  
882 T., Evelyn Ng, S.M., Zhang, W., Hsu, N.Y., et al. (2016). A Frameshift in *CSF2RB*  
883 Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces  
884 Monocyte Signaling via GM-CSF. *Gastroenterology* 151, 710-723 e712.  
885 10.1053/j.gastro.2016.06.045.

886 Chudnovskiy, A., Mortha, A., Kana, V., Kennard, A., Ramirez, J.D., Rahman, A., Remark,  
887 R., Mogno, I., Ng, R., Gnjatic, S., et al. (2016). Host-Protozoan Interactions Protect from  
888 Mucosal Infections through Activation of the Inflammasome. *Cell* 167, 444-456 e414.  
889 10.1016/j.cell.2016.08.076.

890 Dai, X.M., Ryan, G.R., Hapel, A.J., Dominguez, M.G., Russell, R.G., Kapp, S., Sylvestre,  
891 V., and Stanley, E.R. (2002). Targeted disruption of the mouse colony-stimulating factor  
892 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased  
893 primitive progenitor cell frequencies, and reproductive defects. *Blood* 99, 111-120.  
894 10.1182/blood.v99.1.111.

895 Danne, C., Ryzhakov, G., Martinez-Lopez, M., Ilott, N.E., Franchini, F., Cuskin, F., Lowe,  
896 E.C., Bullers, S.J., Arthur, J.S.C., and Powrie, F. (2017). A Large Polysaccharide  
897 Produced by *Helicobacter hepaticus* Induces an Anti-inflammatory Gene Signature in  
898 Macrophages. *Cell Host Microbe* 22, 733-745 e735. 10.1016/j.chom.2017.11.002.

899 De Schepper, S., Verheijden, S., Aguilera-Lizarraga, J., Viola, M.F., Boesmans, W.,  
900 Stakenborg, N., Voytyuk, I., Schmidt, I., Boeckx, B., Dierckx de Casterle, I., et al. (2018).  
901 Self-Maintaining Gut Macrophages Are Essential for Intestinal Homeostasis. *Cell* 175,  
902 400-415 e413. 10.1016/j.cell.2018.07.048.

903 Dick, S.A., Wong, A., Hamidzada, H., Nejat, S., Nechanitzky, R., Vohra, S., Mueller, B.,  
904 Zaman, R., Kantores, C., Aronoff, L., et al. (2022). Three tissue resident macrophage  
905 subsets coexist across organs with conserved origins and life cycles. *Sci Immunol* 7,  
906 eabf7777. 10.1126/sciimmunol.abf7777.

907 Eberl, G., and Lochner, M. (2009). The development of intestinal lymphoid tissues at the  
908 interface of self and microbiota. *Mucosal Immunol* 2, 478-485. 10.1038/mi.2009.114.

909 Goudot, C., Coillard, A., Villani, A.C., Gueguen, P., Cros, A., Sarkizova, S., Tang-Huau,  
910 T.L., Bohec, M., Baulande, S., Hacoheh, N., et al. (2017). Aryl Hydrocarbon Receptor  
911 Controls Monocyte Differentiation into Dendritic Cells versus Macrophages. *Immunity* 47,  
912 582-596 e586. 10.1016/j.immuni.2017.08.016.

913 Greter, M., Lelios, I., Pelczar, P., Hoeffel, G., Price, J., Leboeuf, M., Kundig, T.M., Frei,  
914 K., Ginhoux, F., Merad, M., and Becher, B. (2012). Stroma-derived interleukin-34 controls  
915 the development and maintenance of langerhans cells and the maintenance of microglia.  
916 *Immunity* 37, 1050-1060. 10.1016/j.immuni.2012.11.001.

917 Guendel, F., Kofoed-Branzk, M., Gronke, K., Tizian, C., Witkowski, M., Cheng, H.W.,  
918 Heinz, G.A., Heinrich, F., Durek, P., Norris, P.S., et al. (2020). Group 3 Innate Lymphoid  
919 Cells Program a Distinct Subset of IL-22BP-Producing Dendritic Cells Demarcating  
920 Solitary Intestinal Lymphoid Tissues. *Immunity* 53, 1015-1032 e1018.  
921 10.1016/j.immuni.2020.10.012.

922 Guilliams, M., De Kleer, I., Henri, S., Post, S., Vanhoutte, L., De Prijck, S., Deswarte, K.,  
923 Malissen, B., Hammad, H., and Lambrecht, B.N. (2013). Alveolar macrophages develop  
924 from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-  
925 CSF. *J Exp Med* 210, 1977-1992. 10.1084/jem.20131199.

926 Guilliams, M., Thierry, G.R., Bonnardel, J., and Bajenoff, M. (2020). Establishment and  
927 Maintenance of the Macrophage Niche. *Immunity* 52, 434-451.  
928 10.1016/j.immuni.2020.02.015.

929 Hafemeister, C., and Satija, R. (2019). Normalization and variance stabilization of single-  
930 cell RNA-seq data using regularized negative binomial regression. *Genome Biol* 20, 296.  
931 10.1186/s13059-019-1874-1.

932 Hamada, H., Hiroi, T., Nishiyama, Y., Takahashi, H., Masunaga, Y., Hachimura, S.,  
933 Kaminogawa, S., Takahashi-Iwanaga, H., Iwanaga, T., Kiyono, H., et al. (2002).  
934 Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the  
935 mouse small intestine. *J Immunol* 168, 57-64. 10.4049/jimmunol.168.1.57.

936 Han, X., Uchida, K., Jurickova, I., Koch, D., Willson, T., Samson, C., Bonkowski, E.,  
937 Trauernicht, A., Kim, M.O., Tomer, G., et al. (2009). Granulocyte-macrophage colony-  
938 stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease.  
939 *Gastroenterology* 136, 1261-1271, e1261-1263. 10.1053/j.gastro.2008.12.046.

940 Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., 3rd, Zheng, S., Butler, A., Lee, M.J.,  
941 Wilk, A.J., Darby, C., Zager, M., et al. (2021). Integrated analysis of multimodal single-  
942 cell data. *Cell* 184, 3573-3587 e3529. 10.1016/j.cell.2021.04.048.

943 Hapfelmeier, S., Lawson, M.A., Slack, E., Kirundi, J.K., Stoel, M., Heikenwalder, M.,  
944 Cahenzli, J., Velykoredko, Y., Balmer, M.L., Endt, K., et al. (2010). Reversible microbial  
945 colonization of germ-free mice reveals the dynamics of IgA immune responses. *Science*  
946 328, 1705-1709. 10.1126/science.1188454.

947 Hirata, Y., Egea, L., Dann, S.M., Eckmann, L., and Kagnoff, M.F. (2010). GM-CSF-  
948 facilitated dendritic cell recruitment and survival govern the intestinal mucosal response  
949 to a mouse enteric bacterial pathogen. *Cell Host Microbe* 7, 151-163.  
950 10.1016/j.chom.2010.01.006.

951 Imamura, H., Nhat, K.P., Togawa, H., Saito, K., Iino, R., Kato-Yamada, Y., Nagai, T., and  
952 Noji, H. (2009). Visualization of ATP levels inside single living cells with fluorescence  
953 resonance energy transfer-based genetically encoded indicators. *Proc Natl Acad Sci U S*  
954 *A* 106, 15651-15656. 10.1073/pnas.0904764106.

955 Jones, S.A., Chowdhury, F.Z., Fabich, A.J., Anderson, A., Schreiner, D.M., House, A.L.,  
956 Autieri, S.M., Leatham, M.P., Lins, J.J., Jorgensen, M., et al. (2007). Respiration of  
957 *Escherichia coli* in the mouse intestine. *Infect Immun* 75, 4891-4899. 10.1128/IAI.00484-  
958 07.

959 Kang, B., Alvarado, L.J., Kim, T., Lehmann, M.L., Cho, H., He, J., Li, P., Kim, B.H.,  
960 Larochelle, A., and Kelsall, B.L. (2020). Commensal microbiota drive the functional  
961 diversification of colon macrophages. *Mucosal Immunol* 13, 216-229. 10.1038/s41385-  
962 019-0228-3.

963 Knoop, K.A., Gustafsson, J.K., McDonald, K.G., Kulkarni, D.H., Coughlin, P.E., McCrate,  
964 S., Kim, D., Hsieh, C.S., Hogan, S.P., Elson, C.O., et al. (2017). Microbial antigen  
965 encounter during a preweaning interval is critical for tolerance to gut bacteria. *Sci*  
966 *Immunol* 2. 10.1126/sciimmunol.aao1314.

967 Kosco, B., Kurapati, S., Rodrigues, R.R., Nedjic, J., Gowda, K., Shin, C., Soni, C.,  
968 Ashraf, A.Z., Purushothaman, I., Palisoc, M., et al. (2020). Gut-resident CX3CR1(hi)  
969 macrophages induce tertiary lymphoid structures and IgA response in situ. *Sci Immunol*  
970 5. 10.1126/sciimmunol.aax0062.

971 Liu, Z., Gu, Y., Chakarov, S., Bleriot, C., Kwok, I., Chen, X., Shin, A., Huang, W., Dress,  
972 R.J., Dutertre, C.A., et al. (2019). Fate Mapping via Ms4a3-Expression History Traces  
973 Monocyte-Derived Cells. *Cell* 178, 1509-1525 e1519. 10.1016/j.cell.2019.08.009.

974 Macpherson, A.J., and Uhr, T. (2004). Induction of protective IgA by intestinal dendritic  
975 cells carrying commensal bacteria. *Science* 303, 1662-1665. 10.1126/science.1091334.

976 Matheis, F., Muller, P.A., Graves, C.L., Gabanyi, I., Kerner, Z.J., Costa-Borges, D.,  
977 Ahrends, T., Rosenstiel, P., and Mucida, D. (2020). Adrenergic Signaling in Muscularis  
978 Macrophages Limits Infection-Induced Neuronal Loss. *Cell* 180, 64-78 e16.  
979 10.1016/j.cell.2019.12.002.

980 McQuin, C., Goodman, A., Chernyshev, V., Kametsky, L., Cimini, B.A., Karhohs, K.W.,  
981 Doan, M., Ding, L., Rafelski, S.M., Thirstrup, D., et al. (2018). CellProfiler 3.0: Next-  
982 generation image processing for biology. *PLoS Biol* 16, e2005970.  
983 10.1371/journal.pbio.2005970.

984 Mempin, R., Tran, H., Chen, C., Gong, H., Kim Ho, K., and Lu, S. (2013). Release of  
985 extracellular ATP by bacteria during growth. *BMC Microbiol* 13, 301. 10.1186/1471-2180-  
986 13-301.

987 Mortha, A., Chudnovskiy, A., Hashimoto, D., Bogunovic, M., Spencer, S.P., Belkaid, Y.,  
988 and Merad, M. (2014). Microbiota-dependent crosstalk between macrophages and ILC3  
989 promotes intestinal homeostasis. *Science* 343, 1249288. 10.1126/science.1249288.

990 Mortha, A.e.a. (2021). Anti-GM-CSF autoantibodies promote a “pre-diseased” state in  
991 Crohn’s Disease. *MedRxiv*.

992 Moura Silva, H., Kitoko, J.Z., Queiroz, C.P., Kroehling, L., Matheis, F., Yang, K.L., Reis,  
993 B.S., Ren-Fielding, C., Littman, D.R., Bozza, M.T., et al. (2021). c-MAF-dependent  
994 perivascular macrophages regulate diet-induced metabolic syndrome. *Sci Immunol* 6,  
995 eabg7506. 10.1126/sciimmunol.abg7506.

996 Muller, P.A., Koscsó, B., Rajani, G.M., Stevanovic, K., Berres, M.L., Hashimoto, D.,  
997 Mortha, A., Leboeuf, M., Li, X.M., Mucida, D., et al. (2014). Crosstalk between Muscularis  
998 Macrophages and Enteric Neurons Regulates Gastrointestinal Motility. *Cell* 158, 1210.  
999 10.1016/j.cell.2014.08.002.

1000 O’Flanagan, C.H., Campbell, K.R., Zhang, A.W., Kabeer, F., Lim, J.L.P., Biele, J., Eirew,  
1001 P., Lai, D., McPherson, A., Kong, E., et al. (2019). Dissociation of solid tumor tissues with  
1002 cold active protease for single-cell RNA-seq minimizes conserved collagenase-  
1003 associated stress responses. *Genome Biol* 20, 210. 10.1186/s13059-019-1830-0.

1004 Overacre-Delgoffe, A.E., Bumgarner, H.J., Cillo, A.R., Burr, A.H.P., Tometich, J.T.,  
1005 Bhattacharjee, A., Bruno, T.C., Vignali, D.A.A., and Hand, T.W. (2021). Microbiota-  
1006 specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity

1007 against colorectal cancer. *Immunity* 54, 2812-2824 e2814.  
1008 10.1016/j.immuni.2021.11.003.

1009 Patnode, M.L., Guruge, J.L., Castillo, J.J., Couture, G.A., Lombard, V., Terrapon, N.,  
1010 Henrissat, B., Lebrilla, C.B., and Gordon, J.I. (2021). Strain-level functional variation in  
1011 the human gut microbiota based on bacterial binding to artificial food particles. *Cell Host*  
1012 *Microbe* 29, 664-673 e665. 10.1016/j.chom.2021.01.007.

1013 Perruzza, L., Gargari, G., Proietti, M., Fosso, B., D'Erchia, A.M., Faliti, C.E., Rezzonico-  
1014 Jost, T., Scribano, D., Mauri, L., Colombo, D., et al. (2017). T Follicular Helper Cells  
1015 Promote a Beneficial Gut Ecosystem for Host Metabolic Homeostasis by Sensing  
1016 Microbiota-Derived Extracellular ATP. *Cell Rep* 18, 2566-2575.  
1017 10.1016/j.celrep.2017.02.061.

1018 Qiu, X., Mao, Q., Tang, Y., Wang, L., Chawla, R., Pliner, H.A., and Trapnell, C. (2017).  
1019 Reversed graph embedding resolves complex single-cell trajectories. *Nat Methods* 14,  
1020 979-982. 10.1038/nmeth.4402.

1021 Sankowski, R., Bottcher, C., Masuda, T., Geirsdottir, L., Sagar, Sindram, E., Seredenina,  
1022 T., Muhs, A., Scheiwe, C., Shah, M.J., et al. (2019). Mapping microglia states in the  
1023 human brain through the integration of high-dimensional techniques. *Nat Neurosci* 22,  
1024 2098-2110. 10.1038/s41593-019-0532-y.

1025 Satoh, J., Kino, Y., Asahina, N., Takitani, M., Miyoshi, J., Ishida, T., and Saito, Y. (2016).  
1026 TMEM119 marks a subset of microglia in the human brain. *Neuropathology* 36, 39-49.  
1027 10.1111/neup.12235.

1028 Satoh-Takayama, N., Vosshenrich, C.A., Lesjean-Pottier, S., Sawa, S., Lochner, M.,  
1029 Rattis, F., Mention, J.J., Thiam, K., Cerf-Bensussan, N., Mandelboim, O., et al. (2008).

1030 Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide  
1031 innate mucosal immune defense. *Immunity* 29, 958-970. 10.1016/j.immuni.2008.11.001.  
1032 Schridde, A., Bain, C.C., Mayer, J.U., Montgomery, J., Pollet, E., Denecke, B., Milling,  
1033 S.W.F., Jenkins, S.J., Dalod, M., Henri, S., et al. (2017). Tissue-specific differentiation of  
1034 colonic macrophages requires TGFbeta receptor-mediated signaling. *Mucosal Immunol*  
1035 10, 1387-1399. 10.1038/mi.2016.142.  
1036 Schulthess, J., Pandey, S., Capitani, M., Rue-Albrecht, K.C., Arnold, I., Franchini, F.,  
1037 Chomka, A., Ilott, N.E., Johnston, D.G.W., Pires, E., et al. (2019). The Short Chain Fatty  
1038 Acid Butyrate Imprints an Antimicrobial Program in Macrophages. *Immunity* 50, 432-445  
1039 e437. 10.1016/j.immuni.2018.12.018.  
1040 Scott, C.L., Zheng, F., De Baetselier, P., Martens, L., Saeys, Y., De Prijck, S., Lippens,  
1041 S., Abels, C., Schoonooghe, S., Raes, G., et al. (2016). Bone marrow-derived monocytes  
1042 give rise to self-renewing and fully differentiated Kupffer cells. *Nat Commun* 7, 10321.  
1043 10.1038/ncomms10321.  
1044 Sehgal, A., Donaldson, D.S., Pridans, C., Sauter, K.A., Hume, D.A., and Mabbott, N.A.  
1045 (2018). The role of CSF1R-dependent macrophages in control of the intestinal stem-cell  
1046 niche. *Nat Commun* 9, 1272. 10.1038/s41467-018-03638-6.  
1047 Shaw, T.N., Houston, S.A., Wemyss, K., Bridgeman, H.M., Barbera, T.A., Zangerle-  
1048 Murray, T., Strangward, P., Ridley, A.J.L., Wang, P., Tamoutounour, S., et al. (2018).  
1049 Tissue-resident macrophages in the intestine are long lived and defined by Tim-4 and  
1050 CD4 expression. *J Exp Med* 215, 1507-1518. 10.1084/jem.20180019.  
1051 Song, C., Lee, J.S., Gilfillan, S., Robinette, M.L., Newberry, R.D., Stappenbeck, T.S.,  
1052 Mack, M., Cella, M., and Colonna, M. (2015). Unique and redundant functions of NKp46+



1053 ILC3s in models of intestinal inflammation. *J Exp Med* 212, 1869-1882.  
1054 10.1084/jem.20151403.

1055 Theurl, I., Hilgendorf, I., Nairz, M., Tymoszek, P., Haschka, D., Asshoff, M., He, S.,  
1056 Gerhardt, L.M., Holderried, T.A., Seifert, M., et al. (2016). On-demand erythrocyte  
1057 disposal and iron recycling requires transient macrophages in the liver. *Nat Med* 22, 945-  
1058 951. 10.1038/nm.4146.

1059 Trapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lennon, N.J.,  
1060 Livak, K.J., Mikkelsen, T.S., and Rinn, J.L. (2014). The dynamics and regulators of cell  
1061 fate decisions are revealed by pseudotemporal ordering of single cells. *Nat Biotechnol*  
1062 32, 381-386. 10.1038/nbt.2859.

1063 Tsuji, M., Suzuki, K., Kitamura, H., Maruya, M., Kinoshita, K., Ivanov, I., Itoh, K., Littman,  
1064 D.R., and Fagarasan, S. (2008). Requirement for lymphoid tissue-inducer cells in isolated  
1065 follicle formation and T cell-independent immunoglobulin A generation in the gut.  
1066 *Immunity* 29, 261-271. 10.1016/j.immuni.2008.05.014.

1067 Wan, C.K., Oh, J., Li, P., West, E.E., Wong, E.A., Andraski, A.B., Spolski, R., Yu, Z.X.,  
1068 He, J., Kelsall, B.L., and Leonard, W.J. (2013). The cytokines IL-21 and GM-CSF have  
1069 opposing regulatory roles in the apoptosis of conventional dendritic cells. *Immunity* 38,  
1070 514-527. 10.1016/j.immuni.2013.02.011.

1071 Witmer-Pack, M.D., Hughes, D.A., Schuler, G., Lawson, L., McWilliam, A., Inaba, K.,  
1072 Steinman, R.M., and Gordon, S. (1993). Identification of macrophages and dendritic cells  
1073 in the osteopetrotic (op/op) mouse. *J Cell Sci* 104 ( Pt 4), 1021-1029.  
1074 10.1242/jcs.104.4.1021.

1075




Figure 1




Figure 2




Figure 3





Figure 4






Figure 6






Figure 7













supplemental Figure 1



supplemental Figure 2







supplemental Figure 5

